Chlamydia trachomatis serotype D genes

Abstract

A plasmid isolated from Clamydia trachomatis is described, which comprises 8 genes encoding proteins useful in the formulation of vaccines or diagnostic test for determining the bacterium or specific antibodies generated during C. trachomatis infections; in particular the recombinant fusion MS2-pgp3D protein is described comprising polypeptidic sequences encoded by pCT and immunogenic in the course of infections in man. A method for preparing said protein in E. coli further described.

Description

INVENTION FIELD

This invention refers to the PCTD plasmid isolated from Chlamydia trachomatis serotype D, cloned and sequenced and to the genes present in said plasmid, to the proteins expressed by said genes, to the expression vectors containing said genes and to the microrganisms transformed by said vectors. The invention further refers to the process for the preparation of genes and of said vectors and to the use of said proteins as antigens for the preparation of polyclonal and monoclonal antibodies apt to recognize Chlamydia trachomatis and hence useful for the preparation of vaccines capable of imparting a protective immunity against infections caused by Chlamydia trachomatis and pathologic conditions deriving from said infections and for the development of diagnostic methods for the search of specific antibodies produced following C. trachomatis infections.

PRIOR ART

Chlamydias are gram-negative bacteria, obligate intracellular parasites of eukariotic cells. Chlamydias show an extracellular infective and metabolically practically inert form, called elemental body (EB), and intracellular replicative forms called reticular bodies (RB).

The reticular bodies, after multiplication by binary fission, are transformed into elemental bodies which come out of the host cell and infect new cells.

The masses or mini-colonies of reticular and elemental bodies inside an infected cell constitute the characteristic “inclusions” visible at the optical microscope.

Chlamydia trachomatis ( C. trachomatis or CT ), a bacterial species pathogenic to man, is the etiological agent of venereal lymphogranuloma (VLG), of various inflammatory patologies of the genital male and female apparatus and of trachoma, a chronic disease which affects 500 million people and can lead to blindness. In the technical literature ca. 15 CT serotypes pathogenic to man were described and divided in two groups which differ both as to virulence and tissular tropism.

Twelve serotypes of the trachoma group (biovar) are identified as A to K and infect, in general, epithelial tissues, such as the ocular (trachoma) and uro-genital (cervicitis and urethritis) mucous membranes, and show a low virulence.

The venereal lymphogranuloma (VLG) serotypes (L 1 , L 2 and L 3 ) cause instead an infection of the reticulo-endothelial tissue, mainly of the inguinal and femoral lymphonodi, and are highly invasive. Urethritis and cervicitis induced by CT (A to K serotypes) when not precociously diagnosed and treated by adequate therapy, may led to a variety of chronic inflammations, such as, e.g., vaginitis, salpingities and pelvic inflammation which may resolve in sterility and extrauterine pregnancy.

Furthermore the new born from infected mothers may contract pulmonary and/or ocular infections during delivery.

For said reason it is necessary to possess adequate diagnostic methods for determining CT and formulating effective vaccines against said bacterium.

As known, factors which determine the bacterial virulence are often encoded by genes present on plasmids.

In the literature, the presence is reported, in all 15 serotypes and in the clinical isolates examined up to now, of a plasmid of ca. 7.5 Kb referred to in the present invention as pCT followed by the denomination of the bacterial serotype concerned. For example: pCTD for the plasmid isolated from serotype D, etc.

Up to now, however, no specific function or products encoded by it were associated with said plasmid.

DETAILED DESCRIPTION OF THE INVENTION

A variant of the plasmid, corresponding to serotype D, was now isolated, indicated in what follows a pCTD, which comprises at least eight genes encoding for new proteins.

FIG. 1 a shows the nucleotidic sequence of said plasmid and 7 of the 8 protein structures expressed by said sequence. The eighth protein structure, encoded on the DNA chain complemental to the one of FIG. 1 a , is shown in FIG. 1 b.

Object of the present invention are thus: the cloned and sequenced PCTD plasmid, the nucleotide sequences encoding for the above named proteins, the expression vectors containing one of said sequences or fragments thereof.

Further object of the present invention are the pCTD proteins or fragments of them having immunogenic properties.

Still another object of the present invention are the fusion polypeptides comprising one of said proteins or its fragments suitable as antigens.

The present invention further refers to the preparation of said proteins and of their fragments possessing immunogenic activity or of fused polypeptides comprising said proteins.

Said proteins, their fragments or fusion polypeptides comprising said proteins or their fragments, according to the invention may be employed to determine the CT produced infections in biological samples.

Said proteins, their fragments or fusion polypeptides comprising the protein or its fragments may further be employed, according to the invention, as antigens useful in the formulation of vaccines against infections due to CT.

According to the invention, said proteins, their fragments or fusion polypeptides may be used furthermore as antigens for the preparation of poly- or mono-clonal antibodies to be used in diagnostics.

In particular, the present invention relates to the pgp 3D protein encoded by the gene of the pCTD plasmid identified as ORF3D having the nucleotide sequence reported in FIG. 2 , and characterized by a molecular weight of 27,802 and by the aminoacid sequence reported in FIG. 2 .

According to the present invention, plasmid pCTD is obtained from the C. trachomatis G0/86 strain isolated from the urethra of a patient with non-gonococcic urethritis, and successively identified as serotype D by the immunofluorescence method described by Wang, S. P. and Grayston, J. T. [Am. J. Ophtalmol. 70; 367-374 (1970)].

The ORF3D gene may be isolated from the PCTD plasmid employing one of the known methods such as, e.g., the in vitro amplification method [Saiki, A. K. et al. Science, 239:487-491 (1988)] using as primers synthetic oligonucleotides having a primary structure suitably derived from the sequence data shown in FIGS. 1 a and 1 b . The thus emplified gene is then cloned in a vector placing it under the control of sequences regulating its expression.

One can similarly proceed for the other seven genes the nucleotide sequences of which are reported in FIGS. 1 a and 1 b.

The proteins encoded by said genes are represented by the aminoacid sequences also reported in FIGS. 1 a and 1 b.

Vectors suitable for the ends of the present invention may be plasmids with expression in host cells selected among the ones known and available commercially or at authorized collection centers. The cells transformed by said vectors are then cultivated in a suitable culture medium in the presence of carbon-, nitrogen- and mineral salts sources, possibly in induction conditions, at a temperature and time period selected in order to obtain the production of the desired protein.

Said protein, obtainable also as fused polypeptide, constituted by a polypeptide produced by the vector fused with the protein itself, is then separated and purified from the culture medium or from the cell lysate.

According to one embodiment of the present invention, the ORF3D gene is cloned in the plasmidic E. coli pEX34a vector, a derivative of pEX29 and pEX31 described by Strebel et al. [J.Virol., 57:983-991 (1986)], following the description by Nicosia et al. in Infect. Imm. 1987, Vol.55, 963-967.

The results show the presence in the bacterial extracts of a polypeptide, indicated as MS2-pgp3D, the sequence of which is shown in FIG. 3 , with a mol. weight of ca. 39 Kd, consisting i.e. of a RNA-polymerase fragment of bacteriofage MS2, produced by the expression system of ca. 11 Kd and by the protein encoded by the ORF3D gene of ca. 28 Kd.

Said polypeptide employed as antigen in a Western-Blot assay, or in immunologic assays, is recognized by antibodies present in the serum of patients with CT infection and may further be employed for the production, in laboratory animals, of mono- and poly-clonal antibodies which recognize the − and react with the corresponding pgp3 protein, in all its variants, of C. trachomatis.

In accordance with the present invention the pCTD and p03/60/MCI plasmids were deposited as ATCC N° 68314 and ATCC N° 68315 respectively.

The experimental examples that follow are illustrative and non limitative of the invention.

EXAMPLE 1

Isolation of the pCTD Plasmid from C. trachomatis G0/86

C. trachomatis cells were isolated following known techniques from the urethra of a patient with non-genococcic urethritis. The strain, identified as serotype D by the micro-immunofluorescence technique described by Wang, S. P. and Grayston, J. T. [(1970), Am. J. Ophtalmol., 70: 367-374] is designated as G0/86.

The elemental bodies of said strain are then purified as described by Cevenini R. et al. [(1988), FEMS Microbiol. Letters, 56:41-46] on renografin R density discontinuous gradients (E.R. Squibb & Sons, Princeton, N.J.) according to what reported by Caldwell H. D. et al. [(1988) Infect. Immun. 31:1161-1176].

After purification, the elemental bodies (ca. 1.5 mg proteins) are lysated by incubation in 10 mM Tris-HC1, pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.6% SDS and 100 mg/ml K Proteinase (Boehringer) at 37° C. for 3 hrs. The total nucleic acids are then extracted with phenol/chloroform, precipitated with ethanol, treated with pancreatic RNAse (250 ng/μl final concentration), further precipitated with ethanol and re-suspended in 800 μl water (365 ng/μl of DNA).

A 10 μl aliquot of said solution is then treated with 30 units (U) of BamHI restriction enzyme (Boehringer) at 37° C. for 2 hrs in 20 μl (final volume) of a digestion mixture suggested by the supplier. 3 μl of the resulting digestion mixture are ligated to 100 ng plasmidic pUC8 DNA previously digested with BamHI and dephosphorilated with calf gut phosphatase. The ligase reaction is effected overnight in 20 μl buffer containing 9 U T4 DNA ligase (Boehringer) at 18° C.

The ligation mixture is then employed to transform HB101 E. coli cells made competent by a treatment with CaCl 2 as described by Mandel and Higa [(1970) J. Mol. Biol: 53, 54]. The transformants are selected on LB agar Medium (DIFCO) with addition of 100 μg/ml ampicillin, at 37° C. overnight.

The positive clones (ampicillin resistant) (Amp R ) containing, that is, the recombinant pUC8 plasmid are transferred onto Hybond-N membranes (Amersham) and sorted by hybridization with three 32 P marked oligonucleotides having the following nucleotidic sequences:

1) 5′ATGGGTAAAGGGATTTTATC3′ (SEQ ID NO:1)

2) 5′CTATATTAGAGCCATCTTC3′ (SEQ ID NO:2)

3) 5′TCAAAGCGCTTGCACGAAG3′ (SEQ ID NO:3)

The above reported oligonucleotides are synthesized by means of an automatic synthesizer (Applied Biosystem Inc. Mod. 380A) following the methods and employing the reagents recommended by the manufacturers.

Four of the six plasmids isolated from the clones found positive at the hybridization, analyzed by electrophoresis on agarose 1% gel before and after digestion with BamHI are found to consist of the pUC8 plasmid nucleotidic sequence and of a nucleotidic insert of ca. 7.5 kilobases corresponding to the isolated C .trachomatis G 0/86 plasmid.

The nucleotidic sequences of said insert is determined according to the method of Sanger F. [(1977) PNAS USA 74:5463-5467] utilizing a series of suitable primers. The sequencing reactions are performed on double helix DNA employing the Sequenase Kit (U.S. Biochemical Co. Cleveland, Ohio) as recommended by the firm.

The nucleotidic sequences of the ca. 7.5 kilobases plasmid named pCTD are reported in FIGS. 1 a and 1 b . The recombinant plasmid containing said insert is indicated as pUC8-pCTD.

EXAMPLE 2

Cloning of the DNA ORF3D Segment of Plasmid pCTD1D

The DNA fragment denoted as ORF3D(FIG. 2) of 792 bp is obtained through in vitro amplification according to the technique known as Polymerase Chain Reaction (PCR) described by Saiki A. K. et al. [(1988) Science 239:487-491].

The amplification is effected utilizing ca. 10 ng of the pUC8-pCTD plasmid and employing as primers two synthetic oligonucleotides (ORF31) and (ORF3dx) having respectively the following nucleotide sequences (SEQ ID NO:4 and SEQ ID NO:5):

-5′CAG                                                                        GGATCC                                                                    ATGGGAAATTCTGGTTTTT3′
BamHI
-5′CCC                                                                        CTGCAG                                                                    TTAAGCGTTTGTTTGAGGT3′
Pst I

Said oligonucleotides are complemental to ORF3 regions with the addition to the respective 5′ terminals of a nucleotide sequence comprising the action site of a restriction enzyme selected among the ones present in the pEX34A vector (Strebel K. et al. [(1986, J. Virol.57: 983-991] utilized for the successive cloning. In particular, the site selected for ORF31 is the one for the BamHI enzyme, while for ORF3dx is the one of the PstI enzyme.

The amplification reaction is performed employing the reagents contained in the “Geneamp” Kit (Perkin Elmer-Cetus). 25 amplification cycles are effected. Each amplification cycle consists in heating the reaction mixture to 94° C. for one minute, to 50° C. for one minute and finally to 72° C. for one minute.

At the end of the amplification reaction the mixture is extracted, in succession, with an equal volume of phenol and of a chloroform-isoamyl alcohol mixture (24:1 v/v) and then submitted to forced dialysis by means of Centricon cartridges following the producer's (Amicon) instructions.

The DNA is then precipitated by adding to the obtained solution sodium acetate 3 M, pH 5.5 ({fraction (1/10)} of the volume) and cold (−20° C.) ethanol (3 vols.). The DNA precipitate is dissolved in 44 μl water. To the solution, 5 μl H buffer (Boehringer) and 1 μl PSTI restriction enzyme (20 units/μl) are added and the DNA is digested at 37° C. for 2 hours.

The digestion mixture is then extracted with phenol, chloroform/isoamyl alcohol and then the DNA is precipitated with ethanol (−20° C.). The precipitate, separated by centrifugation, is suspended again in 44 μl water and then digested with 20 U BamHl in 5 μl of B buffer (Boehringer) at 37° C. for 2 hours. The digestion mixture is extracted with phenol, chloroform/isoamyl alcohol and dialyzed by Centricon R cartridge.

At the same time, 10 μg of the pEX34A plasmidic vector are digested with the PstI and BamHI restriction enzymes as reported supra. The vector is dephosphorylated with alkaline phosphatase, extracted with phenol and chloroform/isoamyl alcohol, precipitated with ethanol (−20° C.) and re-suspended in 50 μl water.

1 μl (100 ng) of the vector and 2 μl (200 ng) of the amplified ORF3D segment are then ligated in 2 μl ligase buffer to which 2 μl ATP r, 1 μl T4 DNA ligase (9 units/μl) are added, adding water to a total volume of 20 μl. The ligase reaction is performed at 15° C. overnight. The ligase mixture is employed to transform 200 μl of a suspension of E. coli competent cells (K12-ΔH1-Δtrp) [Remaut E. et al. (1983), Gene 22:103-113]. After treatment at 30° C. for 5 minutes, to the cell suspension 800 μl LB medium are added, followed by incubation at 30° C. for 1 hour. Aliquots of the cell suspension (10 μl, 100 μl and 690 μl) are separately plated on plates of agarized (20 g/l) LB medium containing 100 μg/mg ampicillin and kept at 30° C. overnight.

The obtained clones (Amp R ) are transferred to a nitrocellulose membrane on a LB agar plate with added ampicillin, grown at 30° C. overnight, and then tested for hydridization with three oligonucleotidic probes (UB35, UB36, UB18) terminally marked with 32 P having the following sequences:

I) 5′-ATGGGTAAAGGGATTTTATC3′ (SEQ ID NO:1)

II) 5′-CTATATTAGAGCCATCTTC3′ (SEQ ID NO:2)

III) 5′-TCAAAGCGCTTGCACGAAG3′ (SEQ ID NO:3)

The hybridization test is performed according to known tecnique. From the colonies positive to hybridization the plasmids contained in them are prepared by minipreparation as described by Maniatis et al. (1982) and the ORF3D insert nucleotide sequence is controlled by known technique.

EXAMPLE 3

Expression of the MS2-gpg3 Recombination Protein

E. coli cells containing the pEX34 vector with the ORF3D insert are inoculated in duplicate in 10 ml LB medium with added 30 μg/ml ampicillin and cultivated at 30° C. overnight. The procedure described by Nicosia et al. [Inf. Imm. (1987) 55:963-967] is then followed, with the provision that one of two duplicates undergoes induction of the cloned gene by treatment at 42° C., while the other does not. Two protein extracts are thus obtained, produced by the bacterium, in 7M urea buffered at pH 8, one of which corresponds to the induced cells, and the other, as a control, to the non-induced cells. By analysis of the protein contents of both extracts by electrophoresis in SDS-polyacrylamide 15% gel according to known techniques, it is possible to deduct the presence of a protein species of 39,000 apparent mol.wt. which is present in a considerably greater amount in the induced extracts.

In the non-induced cell lysate no evidence of such a protein, but only the product of the vector alone, is found.

Said electrophoresis patterns may be analyzed by the Western Blot technique employing a monoclonal antibody (SCLAV0) specific for the 11 kd fragment generated by the pEX34 vector. In this way it is possible to demonstrate that the 39 kd band is a fusion protein containing said fragment.

EXAMPLE 4

Purification of MS2-pgp3 from E. coli K12Δ H1Δ trp Extracts

The protein extract, from induced bacterial cells, re-suspended in 7M urea, is dialyzed for 15 hrs. at 4° C. against a PBS buffer consisting of 0.4% KCl, 0.4% KH 2 PO 4 , 16% NaCl, 2.5% NaH 2 PO 4 .

During the dialysis a protein precipitate is obtained, which is separated by centrifuging and discarded. The surnatant is submitted to further purification by electrophoresis on preparative 12.5% acrylamide gels, and the protein band of 39,000 mol.wt. (MS2-pgp3D) is then extracted by electroelution from the gel.

The thus obtained MS2-pgp3 is precipitated by adding to the electroeluted solution 9 volumes of absolute acetone (−20° C.). The protein precipitate is separated by centrifuging, re-suspended in 90% acetone, centrifuged as above, precipitated in 96% acetone and centrifuged again. The precipitate is brought to dryness in a nitrogen stream and re-suspended in 200 μl sterile PBS at a final concentration of approximately 1.5 μg/pl.

The advantage of the effected dialysis is the elimination, with this procedure, of some E. coli proteins, in particular some with a molecular weight equal or very near to the one of the desired recombinant product, which may present a considerable hinderance in the electrophoretic and/or chromatographic purification.

EXAMPLE 5

Production of Polyclonal Anti-MS2-pGPG3 Antibodies

Utilizing the MS2-pgp3 protein, purified as in Example 4, 3 Balb/C 7-8 week old mice are immunized intraperitoneally. The immunization procedure comprises a first injection of 0.2 ml/mouse of an emulsion consisting of one part by vol. of the purified protein solution (1.5 μg/uml) and five parts of Freund complete adjuvant (FCA).

The thus inoculated protein amount is thus ca. 50 μg/mouse.

After 1 week the mice are immunized with the said same emulsion, followed by a 800 μl Pristane injection. After 1 week from the second inoculation, the mice are intraperitoneally immunized with 0.2 ml of a solution similar to the first one. Finally, after two weeks from the third inoculation a booster immunization is effected.

The thus induced antibodies are collected in the ascitic fluid formed after the above described treatment.

The anti MS2-pgp3 antibody titres show values comprised between 1:8000 and 1:10.000 evaluated by analysis with Western Blot containing the MS2-pgp3 protein.

The reactivity of said antibodies to the native antigen (pgp3) was evaluated according to the following methods:

analysis with Western Blot containing total protein extracts of elemental purified CT bodies;

immunofluorescence on McCoy cells cultures infected with CT.

The results of the above tests show that the anti MS2-pgp3 antibodies are able to reveal C. trachomatis inclusions in infected cells (see immunofluorescence test) and recognize a protein present in the bacterium protein extracts and having a mol.wt. of 28 kd, equivalent, that is, to the one of the protein encoded by ORF3D (see Western Blot test).

EXAMPLE 6

To the end of preparing monoclonal anti-MS2-pgp3 antibodies, the mice, immunized as above described, are sacrificed, the spleens extracted and utilized for the preparation of hybridomas operating according to the technique described by Davis L. G. [Basic methods in molecular biology—Elsevier Edit., New York (1986)]. The screening of the thus obtained hybridomas is performed as described for the polyclonal antibodies. In particular, a screening was performed with induced E. coli extracts (see Example 3) containing the MS2-pgp3 protein or the polypeptide encoded by the pEX34 vector alone; obviously, the clones were selected which produced antibodies reacting only with the recombinant product. With such pgp3-specific antibodies, results are obtained which are superimposable to the ones obtained with the above described polyclonal antibodies.

EXAMPLE 7

Serum samples from 20 patients with Chlamydia generated infections were collected. Said sera contained anti-Chlamydia antibodies with titres comprised between 128 and 512, as determined by immunofluorescence against single antigen (LGV2). 15 control sera not containing anti-Chlamydia antibodies were obtained from healty donors. Western Blots were prepared, as above described, containing the MS2-pgp3 protein. These were incubated with the sera under examination diluted 1:100 and successively with peroxidase marked rabbit (anti human IgG) immunoglobines. 16 of the 20 infected patients sera contained antibodies apt to react with MS2-pgp3. The 15 healthy control sera did not give any reaction with said protein.

23 20 base pairs nucleic acid single linear DNA (genomic) unknown 1ATGGGTAAAG GGATTTTATC 20 19 base pairs nucleic acid single linear DNA (genomic) unknown 2CTATATTAGA GCCATCTTC 19 19 base pairs nucleic acid single linear DNA (genomic) unknown 3TCAAAGCGCT TGCACGAAG 19 28 base pairs nucleic acid single linear DNA (genomic) unknown 4CAGGGATCCA TGGGAAATTC TGGTTTTT 28 28 base pairs nucleic acid single linear DNA (genomic) unknown 5CCCCTGCAGT TAAGCGTTTG TTTGAGGT 28 7502 base pairs nucleic acid double circular DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 6ATATTCATAT TCTGTTGCCA GAAAAAACAC CTTTAGGCTA TATTAGAGCC ATCTTCTTTG 60AAGCGTTGTC TTCTCGAGAA GATTTATCGT ACGCAAATAT CATCTTTGCG GTTGCGTGTC 120CTGTGACCTT CATTATGTCG GAGTCTGAGC ACCCTAGGCG TTTGTACTCC GTCACAGCGG 180TTGCTCGAAG CACGTGCGGG GTTATTTTAA AAGGGATTGC AGCTTGTAGT CCTGCTTGAG 240AGAACGTGCG GGCGATTTGC CTTAACCCCA CCATTTTTCC GGAGCGAGTT ACGAAGACAA 300AACCTCTTCG TTGACCGATG TACTCTTGTA GAAAGTGCAT AAACTTCTGA GGATAAGTTA 360TAATAATCCT CTTTTCTGTC TGACGGTTCT TAAGCTGGGA GAAAGAAATG GTAGCTTGTT 420GGAAACAAAT CTGACTAATC TCCAAGCTTA AGACTTCAGA GGAGCGTTTA CCTCCTTGGA 480GCATTGTCTG GGCGATCAAC CAATCCCGGG CATTGATTTT TTTTAGCTCT TTTAGGAAGG 540ATGCTGTTTG CAAACTGTTC ATCGCATCCG TTTTTACTAT TTCCCTGGTT TTAAAAAATG 600TTCGACTATT TTCTTGTTTA GAAGGTTGCG CTATAGCGAC TATTCCTTGA GTCATCCTGT 660TTAGGAATCT TGTTAAGGAA ATATAGCTTG CTGCTCGAAC TTGTTTAGTA CCTTCGGTCC 720AAGAAGTCTT GGCAGAGGAA ACTTTTTTAA TCGCATCTAG GATTAGATTA TGATTTAAAA 780GGGAAAACTC TTGCAGATTC ATATCCAAGG ACAATAGACC AATCTTTTCT AAAGACAAAA 840AAGATCCTCG ATATGATCTA CAAGTATGTT TGTTGAGTGA TGCGGTCCAA TGCATAATAA 900CTTCGAATAA GGAGAAGCTT TTCATGCGTT TCCAATAGGA TTCTTGGCGA ATTTTTAAAA 960CTTCCTGATA AGACTTTTCA CTATATTCTA ACGACATTTC TTGCTGCAAA GATAAAATCC 1020CTTTACCCAT GAAATCCCTC GTGATATAAC CTATCCGTAA AATGTCCTGA TTAGTGAAAT 1080AATCAGGTTG TTAACAGGAT AGCACGCTCG GTATTTTTTT ATATAAACAT GAAAACTCGT 1140TCCGAAATAG AAAATCGCAT GCAAGATATC GAGTATGCGT TGTTAGGTAA AGCTCTGATA 1200TTTGAAGACT CTACTGAGTA TATTCTGAGG CAGCTTGCTA ATTATGAGTT TAAGTGTTCT 1260CATCATAAAA ACATATTCAT AGTATTTAAA CACTTAAAAG ACAATGGATT ACCTATAACT 1320GTAGACTCGG CTTGGGAAGA GCTTTTGCGG CGTCGTATCA AAGATATGGA CAAATCGTAT 1380CTCGGGTTAA TGTTGCATGA TGCTTTATCA AATGACAAGC TTAGATCCGT TTCTCATACG 1440GTTTTCCTCG ATGATTTGAG CGTGTGTAGC GCTGAAGAAA ATTTGAGTAA TTTCATTTTC 1500CGCTCGTTTA ATGAGTACAA TGAAAATCCA TTGCGTAGAT CTCCGTTTCT ATTGCTTGAG 1560CGTATAAAGG GAAGGCTTGA TAGTGCTATA GCAAAGACTT TTTCTATTCG CAGCGCTAGA 1620GGCCGGTCTA TTTATGATAT ATTCTCACAG TCAGAAATTG GAGTGCTGGC TCGTATAAAA 1680AAAAGACGAG TAGCGTTCTC TGAGAATCAA AATTCTTTCT TTGATGGCTT CCCAACAGGA 1740TACAAGGATA TTGATGATAA AGGAGTTATC TTAGCTAAAG GTAATTTCGT GATTATAGCA 1800GCTAGACCAT CTATAGGGAA AACAGCTTTA GCTATAGACA TGGCGATAAA TCTTGCGGTT 1860ACTCAACAGC GTAGAGTTGG TTTCCTATCT CTAGAAATGA GCGCAGGTCA AATTGTTGAG 1920CGGATTATTG CTAATTTAAC AGGAATATCT GGTGAAAAAT TACAAAGAGG GGATCTCTCT 1980AAAGAAGAAT TATTCCGAGT AGAAGAAGCT GGAGAAACGG TTAGAGAATC ACATTTTTAT 2040ATCTGCAGTG ATAGTCAGTA TAAGCTTAAC TTAATCGCGA ATCAGATCCG GTTGCTGAGA 2100AAAGAAGATC GAGTAGACGT AATATTTATC GATTACTTGC AGTTGATCAA CTCATCGGTT 2160GGAGAAAATC GTCAAAATGA AATAGCAGAT ATATCTAGAA CCTTAAGAGG TTTAGCCTCA 2220GAGCTAAACA TTCCTATAGT TTGTTTATCC CAACTATCTA GAAAAGTTGA GGATAGAGCA 2280AATAAAGTTC CCATGCTTTC AGATTTGCGA GACAGCGGTC AAATAGAGCA AGACGCAGAT 2340GTGATTTTGT TTATCAATAG GAAGGAATCG TCTTCTAATT GTGAGATAAC TGTTGGGAAA 2400AATAGACATG GATCGGTTTT CTCTTCGGTA TTACATTTCG ATCCAAAAAT TAGTAAATTC 2460TCCGCTATTA AAAAAGTATG GTAAATTATA GTAACTGCCA CTTCATCAAA AGTCCTATCC 2520ACCTTGAAAA TCAGAAGTTT GGAAGAAGAC CTGGTCAATC TATTAAGATA TCTCCCAAAT 2580TGGCTCAAAA TGGGATGGTA GAAGTTATAG GTCTTGATTT TCTTTCATCT CATTACCATG 2640CATTAGCAGC TATCCAAAGA TTACTGACCG CAACGAATTA CAAGGGGAAC ACAAAAGGGG 2700TTGTTTTATC CAGAGAATCA AATAGTTTTC AATTTGAAGG ATGGATACCA AGAATCCGTT 2760TTACAAAAAC TGAATTCTTA GAGGCTTATG GAGTTAAGCG GTATAAAACA TCCAGAAATA 2820AGTATGAGTT TAGTGGAAAA GAAGCTGAAA CTGCTTTAGA AGCCTTATAC CATTTAGGAC 2880ATCAACCGTT TTTAATAGTG GCAACTAGAA CTCGATGGAC TAATGGAACA CAAATAGTAG 2940ACCGTTACCA AACTCTTTCT CCGATCATTA GGATTTACGA AGGATGGGAA GGTTTAACTG 3000ACGAAGAAAA TATAGATATA GACTTAACAC CTTTTAATTC ACCACCTACA CGGAAACATA 3060AAGGGTTCGT TGTAGAGCCA TGTCCTATCT TGGTAGATCA AATAGAATCC TACTTTGTAA 3120TCAAGCCTGC AAATGTATAC CAAGAAATAA AAATGCGTTT CCCAAATGCA TCAAAGTATG 3180CTTACACATT TATCGACTGG GTGATTACAG CAGCTGCGAA AAAGAGACGA AAATTAACTA 3240AGGATAATTC TTGGCCAGAA AACTTGTTAT TAAACGTTAA CGTTAAAAGT CTTGCATATA 3300TTTTAAGGAT GAATCGGTAC ATCTGTACAA GGAACTGGAA AAAAATCGAG TTAGCTATCG 3360ATAAATGTAT AGAAATCGCC ATTCAGCTTG GCTGGTTATC TAGAAGAAAA CGCATTGAAT 3420TTCTGGATTC TTCTAAACTC TCTAAAAAAG AAATTCTATA TCTAAATAAA GAGCGCTTTG 3480AAGAAATAAC TAAGAAATCT AAAGAACAAA TGGAACAATT AGAACAAGAA TCTATTAATT 3540AATAGCAAGC TTGAAACTAA AAACCTAATT TATTTAAAGC TCAAAATAAA AAAGAGTTTT 3600AAAATGGGAA ATTCTGGTTT TTATTTGTAT AACACTGAAA ACTGCGTCTT TGCTGATAAT 3660ATCAAAGTTG GGCAAATGAC AGAGCCGCTC AAGGACCAGC AAATAATCCT TGGGACAACA 3720TCAACACCTG TCGCAGCCAA AATGACAGCT TCTGATGGAA TATCTTTAAC AGTCTCCAAT 3780AATTCATCAA CCAATGCTTC TATTACAATT GGTTTGGATG CGGAAAAAGC TTACCAGCTT 3840ATTCTAGAAA AGTTGGGAGA TCAAATTCTT GATGGAATTG CTGATACTAT TGTTGATAGT 3900ACAGTCCAAG ATATTTTAGA CAAAATCAAA ACAGACCCTT CTCTAGGTTT GTTGAAAGCT 3960TTTAACAACT TTCCAATCAC TAATAAAATT CAATGCAACG GGTTATTCAC TCCCAGTAAC 4020ATTGAAACTT TATTAGGAGG AACTGAAATA GGAAAATTCA CAGTCACACC CAAAAGCTCT 4080GGGAGCATGT TCTTAGTCTC AGCAGATATT ATTGCATCAA GAATGGAAGG CGGCGTTGTT 4140CTAGCTTTGG TACGAGAAGG TGATTCTAAG CCCTGCGCGA TTAGTTATGG ATACTCATCA 4200GGCATTCCTA ATTTATGTAG TCTAAGAACC AGTATTACTA ATACAGGATT GACTCCGACA 4260ACGTATTCAT TACGTGTAGG CGGTTTAGAA AGCGGTGTGG TATGGGTTAA TGCCCTTTCT 4320AATGGCAATG ATATTTTAGG AATAACAAAT ACTTCTAATG TATCTTTTTT AGAGGTAATA 4380CCTCAAACAA ACGCTTAAAC AATTTTTATT GGATTTTTCT TATAGGTTTT ATATTTAGAG 4440AAAACAGTTC GAATTACGGG GTTTGTTATG CAAAATAAAA GAAAAGTGAG GGACGATTTT 4500ATTAAAATTG TTAAAGATGT GAAAAAAGAT TTCCCCGAAT TAGACCTAAA AATACGAGTA 4560AACAAGGAAA AAGTAACTTT CTTAAATTCT CCCTTAGAAC TCTACCATAA AAGTGTCTCA 4620CTAATTCTAG GACTGCTTCA ACAAATAGAA AACTCTTTAG GATTATTCCC AGACTCTCCT 4680GTTCTTGAAA AATTAGAGGA TAACAGTTTA AAGCTAAAAA AGGCTTTGAT TATGCTTATC 4740TTGTCTAGAA AAGACATGTT TTCCAAGGCT GAATAGACAA CTTACTCTAA CGTTGGAGTT 4800GATTTGCACA CCTTAGTTTT TTGCTCTTTT AAGGGAGGAA CTGGAAAAAC AACACTTTCT 4860CTAAACGTGG GATGCAACTT GGCCCAATTT TTAGGGAAAA AAGTGTTACT TGCTGACCTA 4920GACCCGCAAT CCAATTTATC TTCTGGATTG GGGGCTAGTG TCAGAAGTGA CCAAAAAGGC 4980TTGCACGACA TAGTATACAC ATCAAACGAT TTAAAATCAA TCATTTGCGA AACAAAAAAA 5040GATAGTGTGG ACCTAATTCC TGCATCATTT TCATCCGAAC AGTTTAGAGA ATTGGATATT 5100CATAGAGGAC CTAGTAACAA CTTAAAGTTA TTTCTGAATG AGTACTGCGC TCCTTTTTAT 5160GACATCTGCA TAATAGACAC TCCACCTAGC CTAGGAGGGT TAACGAAAGA AGCTTTTGTT 5220GCAGGAGACA AATTAATTGC TTGTTTAACT CCAGAACCTT TTTCTATTCT AGGGTTACAA 5280AAGATACGTG AATTCTTAAG TTCGGTCGGA AAACCTGAAG AAGAACACAT TCTTGGAATA 5340GCTTTGTCTT TTTGGGATGA TCGTAACTCG ACTAACCAAA TGTATATAGA CATTATCGAG 5400TCTATTTACA AAAACAAGCT TTTTTCAACA AAAATTCGTC GAGATATTTC TCTCAGCCGT 5460TCTCTTCTTA AAGAAGATTC TGTAGCTAAT GTCTATCCAA ATTCTAGGGC CGCAGAAGAT 5520ATTCTGAAGT TAACGCATGA AATAGCAAAT ATTTTGCATA TCGAATATGA ACGAGATTAC 5580TCTCAGAGGA CAACGTGAAC AAACTAAAAA AAGAAGCGGA TGTCTTTTTT AAAAAAAATC 5640AAACTGCCGC TTCTCTAGAT TTTAAGAAGA CGCTTCCCTC CATTGAACTA TTCTCAGCAA 5700CTTTGAATTC TGAGGAAAGT CAGAGTTTGG ATCGATTATT TTTATCAGAG TCCCAAAACT 5760ATTCGGATGA AGAATTTTAT CAAGAAGACA TCCTAGCGGT AAAACTGCTT ACTGGTCAGA 5820TAAAATCCAT ACAGAAGCAA CACGTACTTC TTTTAGGAGA AAAAATCTAT AATGCTAGAA 5880AAATCCTGAG TAAGGATCAC TTCTCCTCAA CAACTTTTTC ATCTTGGATA GAGTTAGTTT 5940TTAGAACTAA GTCTTCTGCT TACAATGCTC TTGCATATTA CGAGCTTTTT ATAAACCTCC 6000CCAACCAAAC TCTACAAAAA GAGTTTCAAT CGATCCCCTA TAAATCCGCA TATATTTTGG 6060CCGCTAGAAA AGGCGATTTA AAAACCAAGG TCGATGTGAT AGGGAAAGTA TGTGGAATGT 6120CGAACTCATC GGCGATAAGG GTGTTGGATC AATTTCTTCC TTCATCTAGA AACAAAGACG 6180TTAGAGAAAC GATAGATAAG TCTGATTCAG AGAAGAATCG CCAATTATCT GATTTCTTAA 6240TAGAGATACT TCGCATCATG TGTTCCGGAG TTTCTTTGTC CTCCTATAAC GAAAATCTTC 6300TACAACAGCT TTTTGAACTT TTTAAGCAAA AGAGCTGATC CTCCGTCAGC TCATATATAT 6360ATATCTATTA TATATATATA TTTAGGGATT TGATTTCACG AGAGAGATTT GCAACTCTTG 6420GTGGTAGACT TTGCAACTCT TGGTGGTAGA CTTTGCAACT CTTGGTGGTA GACTTTGCAA 6480CTCTTGGTGG TAGACTTGGT CATAATGGAC TTTTGTTAAA AAATTTATTA AAATCTTAGA 6540GCTCCGATTT TGAATAGCTT TGGTTAAGAA AATGGGCTCG ATGGCTTTCC ATAAAAGTAG 6600ATTGTTTTTA ACTTTTGGGG ACGCGTCGGA AATTTGGTTA TCTACTTTAT CTTATCTAAC 6660TAGAAAAAAT TATGCGTCTG GGATTAACTT TCTTGTTTCT TTAGAGATTC TGGATTTATC 6720GGAAACCTTG ATAAAGGCTA TTTCTCTTGA CCACAGCGAA TCTTTGTTTA AAATCAAGTC 6780TCTAGATGTT TTTAATGGAA AAGTTGTTTC AGAGGCATCT AAACAGGCTA GAGCGGCATG 6840CTACATATCT TTCACAAAGT TTTTGTATAG ATTGACCAAG GGATATATTA AACCCGCTAT 6900TCCATTGAAA GATTTTGGAA ACACTACATT TTTTAAAATC CGAGACAAAA TCAAAACAGA 6960ATCGATTTCT AAGCAGGAAT GGACAGTTTT TTTTGAAGCG CTCCGGATAG TGAATTATAG 7020AGACTATTTA ATCGGTAAAT TGATTGTACA AGGGATCCGT AAGTTAGACG AAATTTTGTC 7080TTTGCGCACA GACGATCTAT TTTTTGCATC CAATCAGATT TCCTTTCGCA TTAAAAAAAG 7140ACAGAATAAA GAAACCAAAA TTCTAATCAC ATTTCCTATC AGCTTAATGG AAGAGTTGCA 7200AAAATACACT TGTGGGAGAA ATGGGAGAGT ATTTGTTTCT AAAATAGGGA TTCCTGTAAC 7260AACAAGTCAG GTTGCGCATA ATTTTAGGCT TGCAGAGTTC CATAGTGCTA TGAAAATAAA 7320AATTACTCCC AGAGTACTTC GTGCAAGCGC TTTGATTCAT TTAAAGCAAA TAGGATTAAA 7380AGATGAGGAA ATCATGCGTA TTTCCTGTCT TTCATCGAGA CAAAGTGTGT GTTCTTATTG 7440TTCTGGGGAA GAGGTAATTC CTCTAGTACA AACACCCACA ATATTGTGAT ATAATTAAAA 7500TT 7502 1356 base pairs nucleic acid double linear DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 CDS 1..1353 7ATG AAA ACT CGT TCC GAA ATA GAA AAT CGC ATG CAA GAT ATC GAG TAT 48Met Lys Thr Arg Ser Glu Ile Glu Asn Arg Met Gln Asp Ile Glu Tyr 1 5 10 15GCG TTG TTA GGT AAA GCT CTG ATA TTT GAA GAC TCT ACT GAG TAT ATT 96Ala Leu Leu Gly Lys Ala Leu Ile Phe Glu Asp Ser Thr Glu Tyr Ile 20 25 30CTG AGG CAG CTT GCT AAT TAT GAG TTT AAG TGT TCT CAT CAT AAA AAC 144Leu Arg Gln Leu Ala Asn Tyr Glu Phe Lys Cys Ser His His Lys Asn 35 40 45ATA TTC ATA GTA TTT AAA CAC TTA AAA GAC AAT GGA TTA CCT ATA ACT 192Ile Phe Ile Val Phe Lys His Leu Lys Asp Asn Gly Leu Pro Ile Thr 50 55 60GTA GAC TCG GCT TGG GAA GAG CTT TTG CGG CGT CGT ATC AAA GAT ATG 240Val Asp Ser Ala Trp Glu Glu Leu Leu Arg Arg Arg Ile Lys Asp Met 65 70 75 80GAC AAA TCG TAT CTC GGG TTA ATG TTG CAT GAT GCT TTA TCA AAT GAC 288Asp Lys Ser Tyr Leu Gly Leu Met Leu His Asp Ala Leu Ser Asn Asp 85 90 95AAG CTT AGA TCC GTT TCT CAT ACG GTT TTC CTC GAT GAT TTG AGC GTG 336Lys Leu Arg Ser Val Ser His Thr Val Phe Leu Asp Asp Leu Ser Val 100 105 110TGT AGC GCT GAA GAA AAT TTG AGT AAT TTC ATT TTC CGC TCG TTT AAT 384Cys Ser Ala Glu Glu Asn Leu Ser Asn Phe Ile Phe Arg Ser Phe Asn 115 120 125GAG TAC AAT GAA AAT CCA TTG CGT AGA TCT CCG TTT CTA TTG CTT GAG 432Glu Tyr Asn Glu Asn Pro Leu Arg Arg Ser Pro Phe Leu Leu Leu Glu 130 135 140CGT ATA AAG GGA AGG CTT GAT AGT GCT ATA GCA AAG ACT TTT TCT ATT 480Arg Ile Lys Gly Arg Leu Asp Ser Ala Ile Ala Lys Thr Phe Ser Ile145 150 155 160CGC AGC GCT AGA GGC CGG TCT ATT TAT GAT ATA TTC TCA CAG TCA GAA 528Arg Ser Ala Arg Gly Arg Ser Ile Tyr Asp Ile Phe Ser Gln Ser Glu 165 170 175ATT GGA GTG CTG GCT CGT ATA AAA AAA AGA CGA GTA GCG TTC TCT GAG 576Ile Gly Val Leu Ala Arg Ile Lys Lys Arg Arg Val Ala Phe Ser Glu 180 185 190AAT CAA AAT TCT TTC TTT GAT GGC TTC CCA ACA GGA TAC AAG GAT ATT 624Asn Gln Asn Ser Phe Phe Asp Gly Phe Pro Thr Gly Tyr Lys Asp Ile 195 200 205GAT GAT AAA GGA GTT ATC TTA GCT AAA GGT AAT TTC GTG ATT ATA GCA 672Asp Asp Lys Gly Val Ile Leu Ala Lys Gly Asn Phe Val Ile Ile Ala 210 215 220GCT AGA CCA TCT ATA GGG AAA ACA GCT TTA GCT ATA GAC ATG GCG ATA 720Ala Arg Pro Ser Ile Gly Lys Thr Ala Leu Ala Ile Asp Met Ala Ile225 230 235 240AAT CTT GCG GTT ACT CAA CAG CGT AGA GTT GGT TTC CTA TCT CTA GAA 768Asn Leu Ala Val Thr Gln Gln Arg Arg Val Gly Phe Leu Ser Leu Glu 245 250 255ATG AGC GCA GGT CAA ATT GTT GAG CGG ATT ATT GCT AAT TTA ACA GGA 816Met Ser Ala Gly Gln Ile Val Glu Arg Ile Ile Ala Asn Leu Thr Gly 260 265 270ATA TCT GGT GAA AAA TTA CAA AGA GGG GAT CTC TCT AAA GAA GAA TTA 864Ile Ser Gly Glu Lys Leu Gln Arg Gly Asp Leu Ser Lys Glu Glu Leu 275 280 285TTC CGA GTA GAA GAA GCT GGA GAA ACG GTT AGA GAA TCA CAT TTT TAT 912Phe Arg Val Glu Glu Ala Gly Glu Thr Val Arg Glu Ser His Phe Tyr 290 295 300ATC TGC AGT GAT AGT CAG TAT AAG CTT AAC TTA ATC GCG AAT CAG ATC 960Ile Cys Ser Asp Ser Gln Tyr Lys Leu Asn Leu Ile Ala Asn Gln Ile305 310 315 320CGG TTG CTG AGA AAA GAA GAT CGA GTA GAC GTA ATA TTT ATC GAT TAC 1008Arg Leu Leu Arg Lys Glu Asp Arg Val Asp Val Ile Phe Ile Asp Tyr 325 330 335TTG CAG TTG ATC AAC TCA TCG GTT GGA GAA AAT CGT CAA AAT GAA ATA 1056Leu Gln Leu Ile Asn Ser Ser Val Gly Glu Asn Arg Gln Asn Glu Ile 340 345 350GCA GAT ATA TCT AGA ACC TTA AGA GGT TTA GCC TCA GAG CTA AAC ATT 1104Ala Asp Ile Ser Arg Thr Leu Arg Gly Leu Ala Ser Glu Leu Asn Ile 355 360 365CCT ATA GTT TGT TTA TCC CAA CTA TCT AGA AAA GTT GAG GAT AGA GCA 1152Pro Ile Val Cys Leu Ser Gln Leu Ser Arg Lys Val Glu Asp Arg Ala 370 375 380AAT AAA GTT CCC ATG CTT TCA GAT TTG CGA GAC AGC GGT CAA ATA GAG 1200Asn Lys Val Pro Met Leu Ser Asp Leu Arg Asp Ser Gly Gln Ile Glu385 390 395 400CAA GAC GCA GAT GTG ATT TTG TTT ATC AAT AGG AAG GAA TCG TCT TCT 1248Gln Asp Ala Asp Val Ile Leu Phe Ile Asn Arg Lys Glu Ser Ser Ser 405 410 415AAT TGT GAG ATA ACT GTT GGG AAA AAT AGA CAT GGA TCG GTT TTC TCT 1296Asn Cys Glu Ile Thr Val Gly Lys Asn Arg His Gly Ser Val Phe Ser 420 425 430TCG GTA TTA CAT TTC GAT CCA AAA ATT AGT AAA TTC TCC GCT ATT AAA 1344Ser Val Leu His Phe Asp Pro Lys Ile Ser Lys Phe Ser Ala Ile Lys 435 440 445AAA GTA TGG TAA 1356Lys Val Trp 450 451 amino acids amino acid linear protein unknown 8Met Lys Thr Arg Ser Glu Ile Glu Asn Arg Met Gln Asp Ile Glu Tyr 1 5 10 15Ala Leu Leu Gly Lys Ala Leu Ile Phe Glu Asp Ser Thr Glu Tyr Ile 20 25 30Leu Arg Gln Leu Ala Asn Tyr Glu Phe Lys Cys Ser His His Lys Asn 35 40 45Ile Phe Ile Val Phe Lys His Leu Lys Asp Asn Gly Leu Pro Ile Thr 50 55 60Val Asp Ser Ala Trp Glu Glu Leu Leu Arg Arg Arg Ile Lys Asp Met 65 70 75 80Asp Lys Ser Tyr Leu Gly Leu Met Leu His Asp Ala Leu Ser Asn Asp 85 90 95Lys Leu Arg Ser Val Ser His Thr Val Phe Leu Asp Asp Leu Ser Val 100 105 110Cys Ser Ala Glu Glu Asn Leu Ser Asn Phe Ile Phe Arg Ser Phe Asn 115 120 125Glu Tyr Asn Glu Asn Pro Leu Arg Arg Ser Pro Phe Leu Leu Leu Glu 130 135 140Arg Ile Lys Gly Arg Leu Asp Ser Ala Ile Ala Lys Thr Phe Ser Ile145 150 155 160Arg Ser Ala Arg Gly Arg Ser Ile Tyr Asp Ile Phe Ser Gln Ser Glu 165 170 175Ile Gly Val Leu Ala Arg Ile Lys Lys Arg Arg Val Ala Phe Ser Glu 180 185 190Asn Gln Asn Ser Phe Phe Asp Gly Phe Pro Thr Gly Tyr Lys Asp Ile 195 200 205Asp Asp Lys Gly Val Ile Leu Ala Lys Gly Asn Phe Val Ile Ile Ala 210 215 220Ala Arg Pro Ser Ile Gly Lys Thr Ala Leu Ala Ile Asp Met Ala Ile225 230 235 240Asn Leu Ala Val Thr Gln Gln Arg Arg Val Gly Phe Leu Ser Leu Glu 245 250 255Met Ser Ala Gly Gln Ile Val Glu Arg Ile Ile Ala Asn Leu Thr Gly 260 265 270Ile Ser Gly Glu Lys Leu Gln Arg Gly Asp Leu Ser Lys Glu Glu Leu 275 280 285Phe Arg Val Glu Glu Ala Gly Glu Thr Val Arg Glu Ser His Phe Tyr 290 295 300Ile Cys Ser Asp Ser Gln Tyr Lys Leu Asn Leu Ile Ala Asn Gln Ile305 310 315 320Arg Leu Leu Arg Lys Glu Asp Arg Val Asp Val Ile Phe Ile Asp Tyr 325 330 335Leu Gln Leu Ile Asn Ser Ser Val Gly Glu Asn Arg Gln Asn Glu Ile 340 345 350Ala Asp Ile Ser Arg Thr Leu Arg Gly Leu Ala Ser Glu Leu Asn Ile 355 360 365Pro Ile Val Cys Leu Ser Gln Leu Ser Arg Lys Val Glu Asp Arg Ala 370 375 380Asn Lys Val Pro Met Leu Ser Asp Leu Arg Asp Ser Gly Gln Ile Glu385 390 395 400Gln Asp Ala Asp Val Ile Leu Phe Ile Asn Arg Lys Glu Ser Ser Ser 405 410 415Asn Cys Glu Ile Thr Val Gly Lys Asn Arg His Gly Ser Val Phe Ser 420 425 430Ser Val Leu His Phe Asp Pro Lys Ile Ser Lys Phe Ser Ala Ile Lys 435 440 445Lys Val Trp 450 1065 base pairs nucleic acid double linear DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 CDS 1..1062 9ATG GTA AAT TAT AGT AAC TGC CAC TTC ATC AAA AGT CCT ATC CAC CTT 48Met Val Asn Tyr Ser Asn Cys His Phe Ile Lys Ser Pro Ile His Leu 1 5 10 15GAA AAT CAG AAG TTT GGA AGA AGA CCT GGT CAA TCT ATT AAG ATA TCT 96Glu Asn Gln Lys Phe Gly Arg Arg Pro Gly Gln Ser Ile Lys Ile Ser 20 25 30CCC AAA TTG GCT CAA AAT GGG ATG GTA GAA GTT ATA GGT CTT GAT TTT 144Pro Lys Leu Ala Gln Asn Gly Met Val Glu Val Ile Gly Leu Asp Phe 35 40 45CTT TCA TCT CAT TAC CAT GCA TTA GCA GCT ATC CAA AGA TTA CTG ACC 192Leu Ser Ser His Tyr His Ala Leu Ala Ala Ile Gln Arg Leu Leu Thr 50 55 60GCA ACG AAT TAC AAG GGG AAC ACA AAA GGG GTT GTT TTA TCC AGA GAA 240Ala Thr Asn Tyr Lys Gly Asn Thr Lys Gly Val Val Leu Ser Arg Glu 65 70 75 80TCA AAT AGT TTT CAA TTT GAA GGA TGG ATA CCA AGA ATC CGT TTT ACA 288Ser Asn Ser Phe Gln Phe Glu Gly Trp Ile Pro Arg Ile Arg Phe Thr 85 90 95AAA ACT GAA TTC TTA GAG GCT TAT GGA GTT AAG CGG TAT AAA ACA TCC 336Lys Thr Glu Phe Leu Glu Ala Tyr Gly Val Lys Arg Tyr Lys Thr Ser 100 105 110AGA AAT AAG TAT GAG TTT AGT GGA AAA GAA GCT GAA ACT GCT TTA GAA 384Arg Asn Lys Tyr Glu Phe Ser Gly Lys Glu Ala Glu Thr Ala Leu Glu 115 120 125GCC TTA TAC CAT TTA GGA CAT CAA CCG TTT TTA ATA GTG GCA ACT AGA 432Ala Leu Tyr His Leu Gly His Gln Pro Phe Leu Ile Val Ala Thr Arg 130 135 140ACT CGA TGG ACT AAT GGA ACA CAA ATA GTA GAC CGT TAC CAA ACT CTT 480Thr Arg Trp Thr Asn Gly Thr Gln Ile Val Asp Arg Tyr Gln Thr Leu145 150 155 160TCT CCG ATC ATT AGG ATT TAC GAA GGA TGG GAA GGT TTA ACT GAC GAA 528Ser Pro Ile Ile Arg Ile Tyr Glu Gly Trp Glu Gly Leu Thr Asp Glu 165 170 175GAA AAT ATA GAT ATA GAC TTA ACA CCT TTT AAT TCA CCA CCT ACA CGG 576Glu Asn Ile Asp Ile Asp Leu Thr Pro Phe Asn Ser Pro Pro Thr Arg 180 185 190AAA CAT AAA GGG TTC GTT GTA GAG CCA TGT CCT ATC TTG GTA GAT CAA 624Lys His Lys Gly Phe Val Val Glu Pro Cys Pro Ile Leu Val Asp Gln 195 200 205ATA GAA TCC TAC TTT GTA ATC AAG CCT GCA AAT GTA TAC CAA GAA ATA 672Ile Glu Ser Tyr Phe Val Ile Lys Pro Ala Asn Val Tyr Gln Glu Ile 210 215 220AAA ATG CGT TTC CCA AAT GCA TCA AAG TAT GCT TAC ACA TTT ATC GAC 720Lys Met Arg Phe Pro Asn Ala Ser Lys Tyr Ala Tyr Thr Phe Ile Asp225 230 235 240TGG GTG ATT ACA GCA GCT GCG AAA AAG AGA CGA AAA TTA ACT AAG GAT 768Trp Val Ile Thr Ala Ala Ala Lys Lys Arg Arg Lys Leu Thr Lys Asp 245 250 255AAT TCT TGG CCA GAA AAC TTG TTA TTA AAC GTT AAC GTT AAA AGT CTT 816Asn Ser Trp Pro Glu Asn Leu Leu Leu Asn Val Asn Val Lys Ser Leu 260 265 270GCA TAT ATT TTA AGG ATG AAT CGG TAC ATC TGT ACA AGG AAC TGG AAA 864Ala Tyr Ile Leu Arg Met Asn Arg Tyr Ile Cys Thr Arg Asn Trp Lys 275 280 285AAA ATC GAG TTA GCT ATC GAT AAA TGT ATA GAA ATC GCC ATT CAG CTT 912Lys Ile Glu Leu Ala Ile Asp Lys Cys Ile Glu Ile Ala Ile Gln Leu 290 295 300GGC TGG TTA TCT AGA AGA AAA CGC ATT GAA TTT CTG GAT TCT TCT AAA 960Gly Trp Leu Ser Arg Arg Lys Arg Ile Glu Phe Leu Asp Ser Ser Lys305 310 315 320CTC TCT AAA AAA GAA ATT CTA TAT CTA AAT AAA GAG CGC TTT GAA GAA 1008Leu Ser Lys Lys Glu Ile Leu Tyr Leu Asn Lys Glu Arg Phe Glu Glu 325 330 335ATA ACT AAG AAA TCT AAA GAA CAA ATG GAA CAA TTA GAA CAA GAA TCT 1056Ile Thr Lys Lys Ser Lys Glu Gln Met Glu Gln Leu Glu Gln Glu Ser 340 345 350ATT AAT TAA 1065Ile Asn 354 amino acids amino acid linear protein unknown 10Met Val Asn Tyr Ser Asn Cys His Phe Ile Lys Ser Pro Ile His Leu 1 5 10 15Glu Asn Gln Lys Phe Gly Arg Arg Pro Gly Gln Ser Ile Lys Ile Ser 20 25 30Pro Lys Leu Ala Gln Asn Gly Met Val Glu Val Ile Gly Leu Asp Phe 35 40 45Leu Ser Ser His Tyr His Ala Leu Ala Ala Ile Gln Arg Leu Leu Thr 50 55 60Ala Thr Asn Tyr Lys Gly Asn Thr Lys Gly Val Val Leu Ser Arg Glu 65 70 75 80Ser Asn Ser Phe Gln Phe Glu Gly Trp Ile Pro Arg Ile Arg Phe Thr 85 90 95Lys Thr Glu Phe Leu Glu Ala Tyr Gly Val Lys Arg Tyr Lys Thr Ser 100 105 110Arg Asn Lys Tyr Glu Phe Ser Gly Lys Glu Ala Glu Thr Ala Leu Glu 115 120 125Ala Leu Tyr His Leu Gly His Gln Pro Phe Leu Ile Val Ala Thr Arg 130 135 140Thr Arg Trp Thr Asn Gly Thr Gln Ile Val Asp Arg Tyr Gln Thr Leu145 150 155 160Ser Pro Ile Ile Arg Ile Tyr Glu Gly Trp Glu Gly Leu Thr Asp Glu 165 170 175Glu Asn Ile Asp Ile Asp Leu Thr Pro Phe Asn Ser Pro Pro Thr Arg 180 185 190Lys His Lys Gly Phe Val Val Glu Pro Cys Pro Ile Leu Val Asp Gln 195 200 205Ile Glu Ser Tyr Phe Val Ile Lys Pro Ala Asn Val Tyr Gln Glu Ile 210 215 220Lys Met Arg Phe Pro Asn Ala Ser Lys Tyr Ala Tyr Thr Phe Ile Asp225 230 235 240Trp Val Ile Thr Ala Ala Ala Lys Lys Arg Arg Lys Leu Thr Lys Asp 245 250 255Asn Ser Trp Pro Glu Asn Leu Leu Leu Asn Val Asn Val Lys Ser Leu 260 265 270Ala Tyr Ile Leu Arg Met Asn Arg Tyr Ile Cys Thr Arg Asn Trp Lys 275 280 285Lys Ile Glu Leu Ala Ile Asp Lys Cys Ile Glu Ile Ala Ile Gln Leu 290 295 300Gly Trp Leu Ser Arg Arg Lys Arg Ile Glu Phe Leu Asp Ser Ser Lys305 310 315 320Leu Ser Lys Lys Glu Ile Leu Tyr Leu Asn Lys Glu Arg Phe Glu Glu 325 330 335Ile Thr Lys Lys Ser Lys Glu Gln Met Glu Gln Leu Glu Gln Glu Ser 340 345 350Ile Asn 795 base pairs nucleic acid double linear DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 CDS 1..795 11ATG GGA AAT TCT GGT TTT TAT TTG TAT AAC ACT GAA AAC TGC GTC TTT 48Met Gly Asn Ser Gly Phe Tyr Leu Tyr Asn Thr Glu Asn Cys Val Phe 1 5 10 15GCT GAT AAT ATC AAA GTT GGG CAA ATG ACA GAG CCG CTC AAG GAC CAG 96Ala Asp Asn Ile Lys Val Gly Gln Met Thr Glu Pro Leu Lys Asp Gln 20 25 30CAA ATA ATC CTT GGG ACA ACA TCA ACA CCT GTC GCA GCC AAA ATG ACA 144Gln Ile Ile Leu Gly Thr Thr Ser Thr Pro Val Ala Ala Lys Met Thr 35 40 45GCT TCT GAT GGA ATA TCT TTA ACA GTC TCC AAT AAT TCA TCA ACC AAT 192Ala Ser Asp Gly Ile Ser Leu Thr Val Ser Asn Asn Ser Ser Thr Asn 50 55 60GCT TCT ATT ACA ATT GGT TTG GAT GCG GAA AAA GCT TAC CAG CTT ATT 240Ala Ser Ile Thr Ile Gly Leu Asp Ala Glu Lys Ala Tyr Gln Leu Ile 65 70 75 80CTA GAA AAG TTG GGA GAT CAA ATT CTT GAT GGA ATT GCT GAT ACT ATT 288Leu Glu Lys Leu Gly Asp Gln Ile Leu Asp Gly Ile Ala Asp Thr Ile 85 90 95GTT GAT AGT ACA GTC CAA GAT ATT TTA GAC AAA ATC AAA ACA GAC CCT 336Val Asp Ser Thr Val Gln Asp Ile Leu Asp Lys Ile Lys Thr Asp Pro 100 105 110TCT CTA GGT TTG TTG AAA GCT TTT AAC AAC TTT CCA ATC ACT AAT AAA 384Ser Leu Gly Leu Leu Lys Ala Phe Asn Asn Phe Pro Ile Thr Asn Lys 115 120 125ATT CAA TGC AAC GGG TTA TTC ACT CCC AGT AAC ATT GAA ACT TTA TTA 432Ile Gln Cys Asn Gly Leu Phe Thr Pro Ser Asn Ile Glu Thr Leu Leu 130 135 140GGA GGA ACT GAA ATA GGA AAA TTC ACA GTC ACA CCC AAA AGC TCT GGG 480Gly Gly Thr Glu Ile Gly Lys Phe Thr Val Thr Pro Lys Ser Ser Gly145 150 155 160AGC ATG TTC TTA GTC TCA GCA GAT ATT ATT GCA TCA AGA ATG GAA GGC 528Ser Met Phe Leu Val Ser Ala Asp Ile Ile Ala Ser Arg Met Glu Gly 165 170 175GGC GTT GTT CTA GCT TTG GTA CGA GAA GGT GAT TCT AAG CCC TGC GCG 576Gly Val Val Leu Ala Leu Val Arg Glu Gly Asp Ser Lys Pro Cys Ala 180 185 190ATT AGT TAT GGA TAC TCA TCA GGC ATT CCT AAT TTA TGT AGT CTA AGA 624Ile Ser Tyr Gly Tyr Ser Ser Gly Ile Pro Asn Leu Cys Ser Leu Arg 195 200 205ACC AGT ATT ACT AAT ACA GGA TTG ACT CCG ACA ACG TAT TCA TTA CGT 672Thr Ser Ile Thr Asn Thr Gly Leu Thr Pro Thr Thr Tyr Ser Leu Arg 210 215 220GTA GGC GGT TTA GAA AGC GGT GTG GTA TGG GTT AAT GCC CTT TCT AAT 720Val Gly Gly Leu Glu Ser Gly Val Val Trp Val Asn Ala Leu Ser Asn225 230 235 240GGC AAT GAT ATT TTA GGA ATA ACA AAT ACT TCT AAT GTA TCT TTT TTA 768Gly Asn Asp Ile Leu Gly Ile Thr Asn Thr Ser Asn Val Ser Phe Leu 245 250 255GAG GTA ATA CCT CAA ACA AAC GCT TAA 795Glu Val Ile Pro Gln Thr Asn Ala 260 265 264 amino acids amino acid linear protein unknown 12Met Gly Asn Ser Gly Phe Tyr Leu Tyr Asn Thr Glu Asn Cys Val Phe 1 5 10 15Ala Asp Asn Ile Lys Val Gly Gln Met Thr Glu Pro Leu Lys Asp Gln 20 25 30Gln Ile Ile Leu Gly Thr Thr Ser Thr Pro Val Ala Ala Lys Met Thr 35 40 45Ala Ser Asp Gly Ile Ser Leu Thr Val Ser Asn Asn Ser Ser Thr Asn 50 55 60Ala Ser Ile Thr Ile Gly Leu Asp Ala Glu Lys Ala Tyr Gln Leu Ile 65 70 75 80Leu Glu Lys Leu Gly Asp Gln Ile Leu Asp Gly Ile Ala Asp Thr Ile 85 90 95Val Asp Ser Thr Val Gln Asp Ile Leu Asp Lys Ile Lys Thr Asp Pro 100 105 110Ser Leu Gly Leu Leu Lys Ala Phe Asn Asn Phe Pro Ile Thr Asn Lys 115 120 125Ile Gln Cys Asn Gly Leu Phe Thr Pro Ser Asn Ile Glu Thr Leu Leu 130 135 140Gly Gly Thr Glu Ile Gly Lys Phe Thr Val Thr Pro Lys Ser Ser Gly145 150 155 160Ser Met Phe Leu Val Ser Ala Asp Ile Ile Ala Ser Arg Met Glu Gly 165 170 175Gly Val Val Leu Ala Leu Val Arg Glu Gly Asp Ser Lys Pro Cys Ala 180 185 190Ile Ser Tyr Gly Tyr Ser Ser Gly Ile Pro Asn Leu Cys Ser Leu Arg 195 200 205Thr Ser Ile Thr Asn Thr Gly Leu Thr Pro Thr Thr Tyr Ser Leu Arg 210 215 220Val Gly Gly Leu Glu Ser Gly Val Val Trp Val Asn Ala Leu Ser Asn225 230 235 240Gly Asn Asp Ile Leu Gly Ile Thr Asn Thr Ser Asn Val Ser Phe Leu 245 250 255Glu Val Ile Pro Gln Thr Asn Ala 260 309 base pairs nucleic acid double linear DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 CDS 1..309 13ATG CAA AAT AAA AGA AAA GTG AGG GAC GAT TTT ATT AAA ATT GTT AAA 48Met Gln Asn Lys Arg Lys Val Arg Asp Asp Phe Ile Lys Ile Val Lys 1 5 10 15GAT GTG AAA AAA GAT TTC CCC GAA TTA GAC CTA AAA ATA CGA GTA AAC 96Asp Val Lys Lys Asp Phe Pro Glu Leu Asp Leu Lys Ile Arg Val Asn 20 25 30AAG GAA AAA GTA ACT TTC TTA AAT TCT CCC TTA GAA CTC TAC CAT AAA 144Lys Glu Lys Val Thr Phe Leu Asn Ser Pro Leu Glu Leu Tyr His Lys 35 40 45AGT GTC TCA CTA ATT CTA GGA CTG CTT CAA CAA ATA GAA AAC TCT TTA 192Ser Val Ser Leu Ile Leu Gly Leu Leu Gln Gln Ile Glu Asn Ser Leu 50 55 60GGA TTA TTC CCA GAC TCT CCT GTT CTT GAA AAA TTA GAG GAT AAC AGT 240Gly Leu Phe Pro Asp Ser Pro Val Leu Glu Lys Leu Glu Asp Asn Ser 65 70 75 80TTA AAG CTA AAA AAG GCT TTG ATT ATG CTT ATC TTG TCT AGA AAA GAC 288Leu Lys Leu Lys Lys Ala Leu Ile Met Leu Ile Leu Ser Arg Lys Asp 85 90 95ATG TTT TCC AAG GCT GAA TAG 309Met Phe Ser Lys Ala Glu 100 102 amino acids amino acid linear protein unknown 14Met Gln Asn Lys Arg Lys Val Arg Asp Asp Phe Ile Lys Ile Val Lys 1 5 10 15Asp Val Lys Lys Asp Phe Pro Glu Leu Asp Leu Lys Ile Arg Val Asn 20 25 30Lys Glu Lys Val Thr Phe Leu Asn Ser Pro Leu Glu Leu Tyr His Lys 35 40 45Ser Val Ser Leu Ile Leu Gly Leu Leu Gln Gln Ile Glu Asn Ser Leu 50 55 60Gly Leu Phe Pro Asp Ser Pro Val Leu Glu Lys Leu Glu Asp Asn Ser 65 70 75 80Leu Lys Leu Lys Lys Ala Leu Ile Met Leu Ile Leu Ser Arg Lys Asp 85 90 95Met Phe Ser Lys Ala Glu 100 795 base pairs nucleic acid double linear DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 CDS 1..795 15TTG CAC ACC TTA GTT TTT TGC TCT TTT AAG GGA GGA ACT GGA AAA ACA 48Leu His Thr Leu Val Phe Cys Ser Phe Lys Gly Gly Thr Gly Lys Thr 1 5 10 15ACA CTT TCT CTA AAC GTG GGA TGC AAC TTG GCC CAA TTT TTA GGG AAA 96Thr Leu Ser Leu Asn Val Gly Cys Asn Leu Ala Gln Phe Leu Gly Lys 20 25 30AAA GTG TTA CTT GCT GAC CTA GAC CCG CAA TCC AAT TTA TCT TCT GGA 144Lys Val Leu Leu Ala Asp Leu Asp Pro Gln Ser Asn Leu Ser Ser Gly 35 40 45TTG GGG GCT AGT GTC AGA AGT GAC CAA AAA GGC TTG CAC GAC ATA GTA 192Leu Gly Ala Ser Val Arg Ser Asp Gln Lys Gly Leu His Asp Ile Val 50 55 60TAC ACA TCA AAC GAT TTA AAA TCA ATC ATT TGC GAA ACA AAA AAA GAT 240Tyr Thr Ser Asn Asp Leu Lys Ser Ile Ile Cys Glu Thr Lys Lys Asp 65 70 75 80AGT GTG GAC CTA ATT CCT GCA TCA TTT TCA TCC GAA CAG TTT AGA GAA 288Ser Val Asp Leu Ile Pro Ala Ser Phe Ser Ser Glu Gln Phe Arg Glu 85 90 95TTG GAT ATT CAT AGA GGA CCT AGT AAC AAC TTA AAG TTA TTT CTG AAT 336Leu Asp Ile His Arg Gly Pro Ser Asn Asn Leu Lys Leu Phe Leu Asn 100 105 110GAG TAC TGC GCT CCT TTT TAT GAC ATC TGC ATA ATA GAC ACT CCA CCT 384Glu Tyr Cys Ala Pro Phe Tyr Asp Ile Cys Ile Ile Asp Thr Pro Pro 115 120 125AGC CTA GGA GGG TTA ACG AAA GAA GCT TTT GTT GCA GGA GAC AAA TTA 432Ser Leu Gly Gly Leu Thr Lys Glu Ala Phe Val Ala Gly Asp Lys Leu 130 135 140ATT GCT TGT TTA ACT CCA GAA CCT TTT TCT ATT CTA GGG TTA CAA AAG 480Ile Ala Cys Leu Thr Pro Glu Pro Phe Ser Ile Leu Gly Leu Gln Lys145 150 155 160ATA CGT GAA TTC TTA AGT TCG GTC GGA AAA CCT GAA GAA GAA CAC ATT 528Ile Arg Glu Phe Leu Ser Ser Val Gly Lys Pro Glu Glu Glu His Ile 165 170 175CTT GGA ATA GCT TTG TCT TTT TGG GAT GAT CGT AAC TCG ACT AAC CAA 576Leu Gly Ile Ala Leu Ser Phe Trp Asp Asp Arg Asn Ser Thr Asn Gln 180 185 190ATG TAT ATA GAC ATT ATC GAG TCT ATT TAC AAA AAC AAG CTT TTT TCA 624Met Tyr Ile Asp Ile Ile Glu Ser Ile Tyr Lys Asn Lys Leu Phe Ser 195 200 205ACA AAA ATT CGT CGA GAT ATT TCT CTC AGC CGT TCT CTT CTT AAA GAA 672Thr Lys Ile Arg Arg Asp Ile Ser Leu Ser Arg Ser Leu Leu Lys Glu 210 215 220GAT TCT GTA GCT AAT GTC TAT CCA AAT TCT AGG GCC GCA GAA GAT ATT 720Asp Ser Val Ala Asn Val Tyr Pro Asn Ser Arg Ala Ala Glu Asp Ile225 230 235 240CTG AAG TTA ACG CAT GAA ATA GCA AAT ATT TTG CAT ATC GAA TAT GAA 768Leu Lys Leu Thr His Glu Ile Ala Asn Ile Leu His Ile Glu Tyr Glu 245 250 255CGA GAT TAC TCT CAG AGG ACA ACG TGA 795Arg Asp Tyr Ser Gln Arg Thr Thr 260 265 264 amino acids amino acid linear protein unknown 16Leu His Thr Leu Val Phe Cys Ser Phe Lys Gly Gly Thr Gly Lys Thr 1 5 10 15Thr Leu Ser Leu Asn Val Gly Cys Asn Leu Ala Gln Phe Leu Gly Lys 20 25 30Lys Val Leu Leu Ala Asp Leu Asp Pro Gln Ser Asn Leu Ser Ser Gly 35 40 45Leu Gly Ala Ser Val Arg Ser Asp Gln Lys Gly Leu His Asp Ile Val 50 55 60Tyr Thr Ser Asn Asp Leu Lys Ser Ile Ile Cys Glu Thr Lys Lys Asp 65 70 75 80Ser Val Asp Leu Ile Pro Ala Ser Phe Ser Ser Glu Gln Phe Arg Glu 85 90 95Leu Asp Ile His Arg Gly Pro Ser Asn Asn Leu Lys Leu Phe Leu Asn 100 105 110Glu Tyr Cys Ala Pro Phe Tyr Asp Ile Cys Ile Ile Asp Thr Pro Pro 115 120 125Ser Leu Gly Gly Leu Thr Lys Glu Ala Phe Val Ala Gly Asp Lys Leu 130 135 140Ile Ala Cys Leu Thr Pro Glu Pro Phe Ser Ile Leu Gly Leu Gln Lys145 150 155 160Ile Arg Glu Phe Leu Ser Ser Val Gly Lys Pro Glu Glu Glu His Ile 165 170 175Leu Gly Ile Ala Leu Ser Phe Trp Asp Asp Arg Asn Ser Thr Asn Gln 180 185 190Met Tyr Ile Asp Ile Ile Glu Ser Ile Tyr Lys Asn Lys Leu Phe Ser 195 200 205Thr Lys Ile Arg Arg Asp Ile Ser Leu Ser Arg Ser Leu Leu Lys Glu 210 215 220Asp Ser Val Ala Asn Val Tyr Pro Asn Ser Arg Ala Ala Glu Asp Ile225 230 235 240Leu Lys Leu Thr His Glu Ile Ala Asn Ile Leu His Ile Glu Tyr Glu 245 250 255Arg Asp Tyr Ser Gln Arg Thr Thr 260 744 base pairs nucleic acid double linear DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 CDS 1..744 17GTG AAC AAA CTA AAA AAA GAA GCG GAT GTC TTT TTT AAA AAA AAT CAA 48Val Asn Lys Leu Lys Lys Glu Ala Asp Val Phe Phe Lys Lys Asn Gln 1 5 10 15ACT GCC GCT TCT CTA GAT TTT AAG AAG ACG CTT CCC TCC ATT GAA CTA 96Thr Ala Ala Ser Leu Asp Phe Lys Lys Thr Leu Pro Ser Ile Glu Leu 20 25 30TTC TCA GCA ACT TTG AAT TCT GAG GAA AGT CAG AGT TTG GAT CGA TTA 144Phe Ser Ala Thr Leu Asn Ser Glu Glu Ser Gln Ser Leu Asp Arg Leu 35 40 45TTT TTA TCA GAG TCC CAA AAC TAT TCG GAT GAA GAA TTT TAT CAA GAA 192Phe Leu Ser Glu Ser Gln Asn Tyr Ser Asp Glu Glu Phe Tyr Gln Glu 50 55 60GAC ATC CTA GCG GTA AAA CTG CTT ACT GGT CAG ATA AAA TCC ATA CAG 240Asp Ile Leu Ala Val Lys Leu Leu Thr Gly Gln Ile Lys Ser Ile Gln 65 70 75 80AAG CAA CAC GTA CTT CTT TTA GGA GAA AAA ATC TAT AAT GCT AGA AAA 288Lys Gln His Val Leu Leu Leu Gly Glu Lys Ile Tyr Asn Ala Arg Lys 85 90 95ATC CTG AGT AAG GAT CAC TTC TCC TCA ACA ACT TTT TCA TCT TGG ATA 336Ile Leu Ser Lys Asp His Phe Ser Ser Thr Thr Phe Ser Ser Trp Ile 100 105 110GAG TTA GTT TTT AGA ACT AAG TCT TCT GCT TAC AAT GCT CTT GCA TAT 384Glu Leu Val Phe Arg Thr Lys Ser Ser Ala Tyr Asn Ala Leu Ala Tyr 115 120 125TAC GAG CTT TTT ATA AAC CTC CCC AAC CAA ACT CTA CAA AAA GAG TTT 432Tyr Glu Leu Phe Ile Asn Leu Pro Asn Gln Thr Leu Gln Lys Glu Phe 130 135 140CAA TCG ATC CCC TAT AAA TCC GCA TAT ATT TTG GCC GCT AGA AAA GGC 480Gln Ser Ile Pro Tyr Lys Ser Ala Tyr Ile Leu Ala Ala Arg Lys Gly145 150 155 160GAT TTA AAA ACC AAG GTC GAT GTG ATA GGG AAA GTA TGT GGA ATG TCG 528Asp Leu Lys Thr Lys Val Asp Val Ile Gly Lys Val Cys Gly Met Ser 165 170 175AAC TCA TCG GCG ATA AGG GTG TTG GAT CAA TTT CTT CCT TCA TCT AGA 576Asn Ser Ser Ala Ile Arg Val Leu Asp Gln Phe Leu Pro Ser Ser Arg 180 185 190AAC AAA GAC GTT AGA GAA ACG ATA GAT AAG TCT GAT TCA GAG AAG AAT 624Asn Lys Asp Val Arg Glu Thr Ile Asp Lys Ser Asp Ser Glu Lys Asn 195 200 205CGC CAA TTA TCT GAT TTC TTA ATA GAG ATA CTT CGC ATC ATG TGT TCC 672Arg Gln Leu Ser Asp Phe Leu Ile Glu Ile Leu Arg Ile Met Cys Ser 210 215 220GGA GTT TCT TTG TCC TCC TAT AAC GAA AAT CTT CTA CAA CAG CTT TTT 720Gly Val Ser Leu Ser Ser Tyr Asn Glu Asn Leu Leu Gln Gln Leu Phe225 230 235 240GAA CTT TTT AAG CAA AAG AGC TGA 744Glu Leu Phe Lys Gln Lys Ser 245 247 amino acids amino acid linear protein unknown 18Val Asn Lys Leu Lys Lys Glu Ala Asp Val Phe Phe Lys Lys Asn Gln 1 5 10 15Thr Ala Ala Ser Leu Asp Phe Lys Lys Thr Leu Pro Ser Ile Glu Leu 20 25 30Phe Ser Ala Thr Leu Asn Ser Glu Glu Ser Gln Ser Leu Asp Arg Leu 35 40 45Phe Leu Ser Glu Ser Gln Asn Tyr Ser Asp Glu Glu Phe Tyr Gln Glu 50 55 60Asp Ile Leu Ala Val Lys Leu Leu Thr Gly Gln Ile Lys Ser Ile Gln 65 70 75 80Lys Gln His Val Leu Leu Leu Gly Glu Lys Ile Tyr Asn Ala Arg Lys 85 90 95Ile Leu Ser Lys Asp His Phe Ser Ser Thr Thr Phe Ser Ser Trp Ile 100 105 110Glu Leu Val Phe Arg Thr Lys Ser Ser Ala Tyr Asn Ala Leu Ala Tyr 115 120 125Tyr Glu Leu Phe Ile Asn Leu Pro Asn Gln Thr Leu Gln Lys Glu Phe 130 135 140Gln Ser Ile Pro Tyr Lys Ser Ala Tyr Ile Leu Ala Ala Arg Lys Gly145 150 155 160Asp Leu Lys Thr Lys Val Asp Val Ile Gly Lys Val Cys Gly Met Ser 165 170 175Asn Ser Ser Ala Ile Arg Val Leu Asp Gln Phe Leu Pro Ser Ser Arg 180 185 190Asn Lys Asp Val Arg Glu Thr Ile Asp Lys Ser Asp Ser Glu Lys Asn 195 200 205Arg Gln Leu Ser Asp Phe Leu Ile Glu Ile Leu Arg Ile Met Cys Ser 210 215 220Gly Val Ser Leu Ser Ser Tyr Asn Glu Asn Leu Leu Gln Gln Leu Phe225 230 235 240Glu Leu Phe Lys Gln Lys Ser 245 930 base pairs nucleic acid double linear DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 CDS 1..930 19TTG GTT AAG AAA ATG GGC TCG ATG GCT TTC CAT AAA AGT AGA TTG TTT 48Leu Val Lys Lys Met Gly Ser Met Ala Phe His Lys Ser Arg Leu Phe 1 5 10 15TTA ACT TTT GGG GAC GCG TCG GAA ATT TGG TTA TCT ACT TTA TCT TAT 96Leu Thr Phe Gly Asp Ala Ser Glu Ile Trp Leu Ser Thr Leu Ser Tyr 20 25 30CTA ACT AGA AAA AAT TAT GCG TCT GGG ATT AAC TTT CTT GTT TCT TTA 144Leu Thr Arg Lys Asn Tyr Ala Ser Gly Ile Asn Phe Leu Val Ser Leu 35 40 45GAG ATT CTG GAT TTA TCG GAA ACC TTG ATA AAG GCT ATT TCT CTT GAC 192Glu Ile Leu Asp Leu Ser Glu Thr Leu Ile Lys Ala Ile Ser Leu Asp 50 55 60CAC AGC GAA TCT TTG TTT AAA ATC AAG TCT CTA GAT GTT TTT AAT GGA 240His Ser Glu Ser Leu Phe Lys Ile Lys Ser Leu Asp Val Phe Asn Gly 65 70 75 80AAA GTT GTT TCA GAG GCA TCT AAA CAG GCT AGA GCG GCA TGC TAC ATA 288Lys Val Val Ser Glu Ala Ser Lys Gln Ala Arg Ala Ala Cys Tyr Ile 85 90 95TCT TTC ACA AAG TTT TTG TAT AGA TTG ACC AAG GGA TAT ATT AAA CCC 336Ser Phe Thr Lys Phe Leu Tyr Arg Leu Thr Lys Gly Tyr Ile Lys Pro 100 105 110GCT ATT CCA TTG AAA GAT TTT GGA AAC ACT ACA TTT TTT AAA ATC CGA 384Ala Ile Pro Leu Lys Asp Phe Gly Asn Thr Thr Phe Phe Lys Ile Arg 115 120 125GAC AAA ATC AAA ACA GAA TCG ATT TCT AAG CAG GAA TGG ACA GTT TTT 432Asp Lys Ile Lys Thr Glu Ser Ile Ser Lys Gln Glu Trp Thr Val Phe 130 135 140TTT GAA GCG CTC CGG ATA GTG AAT TAT AGA GAC TAT TTA ATC GGT AAA 480Phe Glu Ala Leu Arg Ile Val Asn Tyr Arg Asp Tyr Leu Ile Gly Lys145 150 155 160TTG ATT GTA CAA GGG ATC CGT AAG TTA GAC GAA ATT TTG TCT TTG CGC 528Leu Ile Val Gln Gly Ile Arg Lys Leu Asp Glu Ile Leu Ser Leu Arg 165 170 175ACA GAC GAT CTA TTT TTT GCA TCC AAT CAG ATT TCC TTT CGC ATT AAA 576Thr Asp Asp Leu Phe Phe Ala Ser Asn Gln Ile Ser Phe Arg Ile Lys 180 185 190AAA AGA CAG AAT AAA GAA ACC AAA ATT CTA ATC ACA TTT CCT ATC AGC 624Lys Arg Gln Asn Lys Glu Thr Lys Ile Leu Ile Thr Phe Pro Ile Ser 195 200 205TTA ATG GAA GAG TTG CAA AAA TAC ACT TGT GGG AGA AAT GGG AGA GTA 672Leu Met Glu Glu Leu Gln Lys Tyr Thr Cys Gly Arg Asn Gly Arg Val 210 215 220TTT GTT TCT AAA ATA GGG ATT CCT GTA ACA ACA AGT CAG GTT GCG CAT 720Phe Val Ser Lys Ile Gly Ile Pro Val Thr Thr Ser Gln Val Ala His225 230 235 240AAT TTT AGG CTT GCA GAG TTC CAT AGT GCT ATG AAA ATA AAA ATT ACT 768Asn Phe Arg Leu Ala Glu Phe His Ser Ala Met Lys Ile Lys Ile Thr 245 250 255CCC AGA GTA CTT CGT GCA AGC GCT TTG ATT CAT TTA AAG CAA ATA GGA 816Pro Arg Val Leu Arg Ala Ser Ala Leu Ile His Leu Lys Gln Ile Gly 260 265 270TTA AAA GAT GAG GAA ATC ATG CGT ATT TCC TGT CTT TCA TCG AGA CAA 864Leu Lys Asp Glu Glu Ile Met Arg Ile Ser Cys Leu Ser Ser Arg Gln 275 280 285AGT GTG TGT TCT TAT TGT TCT GGG GAA GAG GTA ATT CCT CTA GTA CAA 912Ser Val Cys Ser Tyr Cys Ser Gly Glu Glu Val Ile Pro Leu Val Gln 290 295 300ACA CCC ACA ATA TTG TGA 930Thr Pro Thr Ile Leu305 310 309 amino acids amino acid linear protein unknown 20Leu Val Lys Lys Met Gly Ser Met Ala Phe His Lys Ser Arg Leu Phe 1 5 10 15Leu Thr Phe Gly Asp Ala Ser Glu Ile Trp Leu Ser Thr Leu Ser Tyr 20 25 30Leu Thr Arg Lys Asn Tyr Ala Ser Gly Ile Asn Phe Leu Val Ser Leu 35 40 45Glu Ile Leu Asp Leu Ser Glu Thr Leu Ile Lys Ala Ile Ser Leu Asp 50 55 60His Ser Glu Ser Leu Phe Lys Ile Lys Ser Leu Asp Val Phe Asn Gly 65 70 75 80Lys Val Val Ser Glu Ala Ser Lys Gln Ala Arg Ala Ala Cys Tyr Ile 85 90 95Ser Phe Thr Lys Phe Leu Tyr Arg Leu Thr Lys Gly Tyr Ile Lys Pro 100 105 110Ala Ile Pro Leu Lys Asp Phe Gly Asn Thr Thr Phe Phe Lys Ile Arg 115 120 125Asp Lys Ile Lys Thr Glu Ser Ile Ser Lys Gln Glu Trp Thr Val Phe 130 135 140Phe Glu Ala Leu Arg Ile Val Asn Tyr Arg Asp Tyr Leu Ile Gly Lys145 150 155 160Leu Ile Val Gln Gly Ile Arg Lys Leu Asp Glu Ile Leu Ser Leu Arg 165 170 175Thr Asp Asp Leu Phe Phe Ala Ser Asn Gln Ile Ser Phe Arg Ile Lys 180 185 190Lys Arg Gln Asn Lys Glu Thr Lys Ile Leu Ile Thr Phe Pro Ile Ser 195 200 205Leu Met Glu Glu Leu Gln Lys Tyr Thr Cys Gly Arg Asn Gly Arg Val 210 215 220Phe Val Ser Lys Ile Gly Ile Pro Val Thr Thr Ser Gln Val Ala His225 230 235 240Asn Phe Arg Leu Ala Glu Phe His Ser Ala Met Lys Ile Lys Ile Thr 245 250 255Pro Arg Val Leu Arg Ala Ser Ala Leu Ile His Leu Lys Gln Ile Gly 260 265 270Leu Lys Asp Glu Glu Ile Met Arg Ile Ser Cys Leu Ser Ser Arg Gln 275 280 285Ser Val Cys Ser Tyr Cys Ser Gly Glu Glu Val Ile Pro Leu Val Gln 290 295 300Thr Pro Thr Ile Leu305 993 base pairs nucleic acid double linear DNA (genomic) Chlamydia trachomatis GO/86 serotype D ( trachoma biovar ) pUC8-pGO plasmid, ATCC 68314 CDS 1..993 21ATG GGT AAA GGG ATT TTA TCT TTG CAG CAA GAA ATG TCG TTA GAA TAT 48Met Gly Lys Gly Ile Leu Ser Leu Gln Gln Glu Met Ser Leu Glu Tyr 1 5 10 15AGT GAA AAG TCT TAT CAG GAA GTT TTA AAA ATT CGC CAA GAA TCC TAT 96Ser Glu Lys Ser Tyr Gln Glu Val Leu Lys Ile Arg Gln Glu Ser Tyr 20 25 30TGG AAA CGC ATG AAA AGC TTC TCC TTA TTC GAA GTT ATT ATG CAT TGG 144Trp Lys Arg Met Lys Ser Phe Ser Leu Phe Glu Val Ile Met His Trp 35 40 45ACC GCA TCA CTC AAC AAA CAT ACT TGT AGA TCA TAT CGA GGA TCT TTT 192Thr Ala Ser Leu Asn Lys His Thr Cys Arg Ser Tyr Arg Gly Ser Phe 50 55 60TTG TCT TTA GAA AAG ATT GGT CTA TTG TCC TTG GAT ATG AAT CTG CAA 240Leu Ser Leu Glu Lys Ile Gly Leu Leu Ser Leu Asp Met Asn Leu Gln 65 70 75 80GAG TTT TCC CTT TTA AAT CAT AAT CTA ATC CTA GAT GCG ATT AAA AAA 288Glu Phe Ser Leu Leu Asn His Asn Leu Ile Leu Asp Ala Ile Lys Lys 85 90 95GTT TCC TCT GCC AAG ACT TCT TGG ACC GAA GGT ACT AAA CAA GTT CGA 336Val Ser Ser Ala Lys Thr Ser Trp Thr Glu Gly Thr Lys Gln Val Arg 100 105 110GCA GCA AGC TAT ATT TCC TTA ACA AGA TTC CTA AAC AGG ATG ACT CAA 384Ala Ala Ser Tyr Ile Ser Leu Thr Arg Phe Leu Asn Arg Met Thr Gln 115 120 125GGA ATA GTC GCT ATA GCG CAA CCT TCT AAA CAA GAA AAT AGT CGA ACA 432Gly Ile Val Ala Ile Ala Gln Pro Ser Lys Gln Glu Asn Ser Arg Thr 130 135 140TTT TTT AAA ACC AGG GAA ATA GTA AAA ACG GAT GCG ATG AAC AGT TTG 480Phe Phe Lys Thr Arg Glu Ile Val Lys Thr Asp Ala Met Asn Ser Leu145 150 155 160CAA ACA GCA TCC TTC CTA AAA GAG CTA AAA AAA ATC AAT GCC CGG GAT 528Gln Thr Ala Ser Phe Leu Lys Glu Leu Lys Lys Ile Asn Ala Arg Asp 165 170 175TGG TTG ATC GCC CAG ACA ATG CTC CAA GGA GGT AAA CGC TCC TCT GAA 576Trp Leu Ile Ala Gln Thr Met Leu Gln Gly Gly Lys Arg Ser Ser Glu 180 185 190GTC TTA AGC TTG GAG ATT AGT CAG ATT TGT TTC CAA CAA GCT ACC ATT 624Val Leu Ser Leu Glu Ile Ser Gln Ile Cys Phe Gln Gln Ala Thr Ile 195 200 205TCT TTC TCC CAG CTT AAG AAC CGT CAG ACA GAA AAG AGG ATT ATT ATA 672Ser Phe Ser Gln Leu Lys Asn Arg Gln Thr Glu Lys Arg Ile Ile Ile 210 215 220ACT TAT CCT CAG AAG TTT ATG CAC TTT CTA CAA GAG TAC ATC GGT CAA 720Thr Tyr Pro Gln Lys Phe Met His Phe Leu Gln Glu Tyr Ile Gly Gln225 230 235 240CGA AGA GGT TTT GTC TTC GTA ACT CGC TCC GGA AAA ATG GTG GGG TTA 768Arg Arg Gly Phe Val Phe Val Thr Arg Ser Gly Lys Met Val Gly Leu 245 250 255AGG CAA ATC GCC CGC ACG TTC TCT CAA GCA GGA CTA CAA GCT GCA ATC 816Arg Gln Ile Ala Arg Thr Phe Ser Gln Ala Gly Leu Gln Ala Ala Ile 260 265 270CCT TTT AAA ATA ACC CCG CAC GTG CTT CGA GCA ACC GCT GTG ACG GAG 864Pro Phe Lys Ile Thr Pro His Val Leu Arg Ala Thr Ala Val Thr Glu 275 280 285TAC AAA CGC CTA GGG TGC TCA GAC TCC GAC ATA ATG AAG GTC ACA GGA 912Tyr Lys Arg Leu Gly Cys Ser Asp Ser Asp Ile Met Lys Val Thr Gly 290 295 300CAC GCA ACC GCA AAG ATG ATA TTT GCG TAC GAT AAA TCT TCT CGA GAA 960His Ala Thr Ala Lys Met Ile Phe Ala Tyr Asp Lys Ser Ser Arg Glu305 310 315 320GAC AAC GCT TCA AAG AAG ATG GCT CTA ATA TAG 993Asp Asn Ala Ser Lys Lys Met Ala Leu Ile 325 330 330 amino acids amino acid linear protein unknown 22Met Gly Lys Gly Ile Leu Ser Leu Gln Gln Glu Met Ser Leu Glu Tyr 1 5 10 15Ser Glu Lys Ser Tyr Gln Glu Val Leu Lys Ile Arg Gln Glu Ser Tyr 20 25 30Trp Lys Arg Met Lys Ser Phe Ser Leu Phe Glu Val Ile Met His Trp 35 40 45Thr Ala Ser Leu Asn Lys His Thr Cys Arg Ser Tyr Arg Gly Ser Phe 50 55 60Leu Ser Leu Glu Lys Ile Gly Leu Leu Ser Leu Asp Met Asn Leu Gln 65 70 75 80Glu Phe Ser Leu Leu Asn His Asn Leu Ile Leu Asp Ala Ile Lys Lys 85 90 95Val Ser Ser Ala Lys Thr Ser Trp Thr Glu Gly Thr Lys Gln Val Arg 100 105 110Ala Ala Ser Tyr Ile Ser Leu Thr Arg Phe Leu Asn Arg Met Thr Gln 115 120 125Gly Ile Val Ala Ile Ala Gln Pro Ser Lys Gln Glu Asn Ser Arg Thr 130 135 140Phe Phe Lys Thr Arg Glu Ile Val Lys Thr Asp Ala Met Asn Ser Leu145 150 155 160Gln Thr Ala Ser Phe Leu Lys Glu Leu Lys Lys Ile Asn Ala Arg Asp 165 170 175Trp Leu Ile Ala Gln Thr Met Leu Gln Gly Gly Lys Arg Ser Ser Glu 180 185 190Val Leu Ser Leu Glu Ile Ser Gln Ile Cys Phe Gln Gln Ala Thr Ile 195 200 205Ser Phe Ser Gln Leu Lys Asn Arg Gln Thr Glu Lys Arg Ile Ile Ile 210 215 220Thr Tyr Pro Gln Lys Phe Met His Phe Leu Gln Glu Tyr Ile Gly Gln225 230 235 240Arg Arg Gly Phe Val Phe Val Thr Arg Ser Gly Lys Met Val Gly Leu 245 250 255Arg Gln Ile Ala Arg Thr Phe Ser Gln Ala Gly Leu Gln Ala Ala Ile 260 265 270Pro Phe Lys Ile Thr Pro His Val Leu Arg Ala Thr Ala Val Thr Glu 275 280 285Tyr Lys Arg Leu Gly Cys Ser Asp Ser Asp Ile Met Lys Val Thr Gly 290 295 300His Ala Thr Ala Lys Met Ile Phe Ala Tyr Asp Lys Ser Ser Arg Glu305 310 315 320Asp Asn Ala Ser Lys Lys Met Ala Leu Ile 325 330 370 amino acids amino acid linear protein unknown E. coli ATCC 68315 plasmid P03/GO/MC1 Region 1..370 /label= polypeptide /note= “polypeptide is a fusion protein of the RNA-polymerase from bacteriophage MS2 and the protein encoded by the ORF3D gene of C. Region 107..370 /label= region /note= ”this portion of the fusion protein is the protein encoded by the ORF3D gene.“ Region 1..106 /label= region /note= ”this portion of the fusion protein is a fragment of the RNA polymerase gene from the bacteriophage MS2.“ 23Met Ser Lys Thr Thr Lys Lys Phe Asn Ser Leu Cys Ile Asp Leu Pro1 5 10 15Arg Asp Leu Ser Leu Glu Ile Tyr Gln Ser Ile Ala Ser Val Ala Thr 20 25 30Gly Ser Gly Asp Pro His Ser Asp Asp Phe Thr Ala Ile Ala Tyr Leu 35 40 45Arg Asp Glu Leu Leu Thr Lys His Pro Thr Leu Gly Ser Gly Asn Asp 50 55 60Glu Ala Thr Arg Arg Thr Leu Ala Ile Ala Lys Leu Arg Glu Ala Asn65 70 75 80Gly Asp Arg Gly Gln Ile Asn Arg Glu Gly Phe Leu His Asp Lys Ser 85 90 95Leu Ser Trp Asp Ile Arg Ala Thr Gly Ser Met Gly Asn Ser Gly Phe 100 105 110Tyr Leu Tyr Asn Thr Glu Asn Cys Val Phe Ala Asp Asn Ile Lys Val 115 120 125Gly Gln Met Thr Glu Pro Leu Lys Asp Gln Gln Ile Ile Leu Gly Thr 130 135 140Thr Ser Thr Pro Val Ala Ala Lys Met Thr Ala Ser Asp Gly Ile Ser145 150 155 160Leu Thr Val Ser Asn Asn Ser Ser Thr Asn Ala Ser Ile Thr Ile Gly 165 170 175Leu Asp Ala Glu Lys Ala Tyr Gln Leu Ile Leu Glu Lys Leu Gly Asp 180 185 190Gln Ile Leu Asp Gly Ile Ala Asp Thr Ile Val Asp Ser Thr Val Gln 195 200 205Asp Ile Leu Asp Lys Ile Lys Thr Asp Pro Ser Leu Gly Leu Leu Lys 210 215 220Ala Phe Asn Asn Phe Pro Ile Thr Asn Lys Ile Gln Cys Asn Gly Leu225 230 235 240Phe Thr Pro Ser Asn Ile Glu Thr Leu Leu Gly Gly Thr Glu Ile Gly 245 250 255Lys Phe Thr Val Thr Pro Lys Ser Ser Gly Ser Met Phe Leu Val Ser 260 265 270Ala Asp Ile Ile Ala Ser Arg Met Glu Gly Gly Val Val Leu Ala Leu 275 280 285Val Arg Glu Gly Asp Ser Lys Pro Cys Ala Ile Ser Tyr Gly Tyr Ser 290 295 300Ser Gly Ile Pro Asn Leu Cys Ser Leu Arg Thr Ser Ile Thr Asn Thr305 310 315 320Gly Leu Thr Pro Thr Thr Tyr Ser Leu Arg Val Gly Gly Leu Glu Ser 325 330 335Gly Val Val Trp Val Asn Ala Leu Ser Asn Gly Asn Asp Ile Leu Gly 340 345 350Ile Thr Asn Thr Ser Asn Val Ser Phe Leu Glu Val Ile Pro Gln Thr 355 360 365Asn Ala 370

Claims

1. A pCTD plasmid isolated from Chlamydia trachomatis serotype D comprising the following nucleotide sequence:            10                  30SEQ ID NO:6    ATATTCATATTCTGTTGCCAGAAAAAACAC                      50    CTTTAGGCTATATTAGAGCCATCTTCTTTG            70                  90    AAGCGTTGTCTTCTCGAGAAGATTTATCGT                      110    ACGCAAATATCATCTTTGCGGTTGCGTGTC           130                 150    CTGTGACCTTCATTATGTCGGAGTCTGAGC                     170    ACCCTAGGCGTTTGTACTCCGTCACAGCGG           190                 210    TTGCTCGAAGCACGTGCGGGGTTATTTTAA                     230    AAGGGATTGCAGCTTGTAGTCCTGCTTGAG           250                 270    AGAACGTGCGGGCGATTTGCCTTAACCCCA                     290    CCATTTTTCCGGAGCGAGTTACGAAGACAA           310                 330    AACCTCTTCGTTGACCGATGTACTCTTGTA                     350    GAAAGTGCATAAACTTCTGAGGATAAGTTA           370                 390    TAATAATCCTCTTTTCTGTCTGACGGTTCT                     410    TAAGCTGGGAGAAAGAAATGGTAGCTTGTT           430                 450    GGAAACAAATCTGACTAATCTCCAAGCTTA                     470    AGACTTCAGAGGAGCGTTTACCTCCTTGGA           490                 510    GCATTGTCTGGGCGATCAACCAATCCCGGG                     530    CATTGATTTTTTTTAGCTCTTTTAGGAAGG           550                 570    ATGCTGTTTGCAAACTGTTCATCGCATCCG                     590    TTTTTACTATTTCCCTGGTTTTAAAAAATG           610                 630    TTCGACTATTTTCTTGTTTAGAAGGTTGCG                     650    CTATAGCGACTATTCCTTGAGTCATCCTGT           670                 690    TTAGGAATCTTGTTAAGGAAATATAGCTTG                     710    CTGCTCGAACTTGTTTAGTACCTTCGGTCC           730                 750    AAGAAGTCTTGGCAGAGGAAACTTTTTTAA                     770    TCGCATCTAGGATTAGATTATGATTTAAAA           790                 810    GGGAAAACTCTTGCAGATTCATATCCAAGG                     830    ACAATAGACCAATCTTTTCTAAAGACAAAA           850                 870    AAGATCCTCGATATGATCTACAAGTATGTT                     890    TGTTGAGTGATGCGGTCCAATGCATAATAA           910                 930    CTTCGAATAAGGAGAAGCTTTTCATGCGTT                     950    TCCAATAGGATTCTTGGCGAATTTTTAAAA           970                 990    CTTCCTGATAAGACTTTTCACTATATTCTA                    1010    ACGACATTTCTTGCTGCAAAGATAAAATCC          1030                1050    CTTTACCCATGAAATCCCTCGTGATATAAC                    1070    CTATCCGTAAAATGTCCTGATTAGTGAAAT          1090                1110    AATCAGGTTGTTAACAGGATAGCACGCTCG                    1130    GTATTTTTTTATATAAACATGAAAACTCGT             ORF1 >>          1150                1170    TCCGAAATAGAAAATCGCATGCAAGATATC                    1190    GAGTATGCGTTGTTAGGTAAAGCTCTGATA          1210                1230    TTTGAAGACTCTACTGAGTATATTCTGAGG                    1250    CAGCTTGCTAATTATGAGTTTAAGTGTTCT          1270                1290    CATCATAAAAACATATTCATAGTATTTAAA                    1310    CACTTAAAAGACAATGGATTACCTATAACT          1330                1350    GTAGACTCGGCTTGGGAAGAGCTTTTGCGG                    1370    CGTCGTATCAAAGATATGGACAAATCGTAT          1390                1410    CTCGGGTTAATGTTGCATGATGCTTTATCA                    1430    AATGACAAGCTTAGATCCGTTTCTCATACG          1450                1470    GTTTTCCTCGATGATTTGAGCGTGTGTAGC                    1490    GCTGAAGAAAATTTGAGTAATTTCATTTTC          1510                1530    CGCTCGTTTAATGAGTACAATGAAAATCCA                    1550    TTGAGTAGATCTCCGTTTCTATTGCTTGAG          1570                1590    CGTATAAAGGGAAGGCTTGATAGTGCTATA                    1610    GCAAAGACTTTTTCTATTCGCAGCGCTAGA          1630                1650    GGCCGGTCTATTTATGATATATTCTCACAG                    1670    TCAGAAATTGGAGTGCTGGCTCGTATAAAA          1690                1710    AAAAGACGAGTAGCGTTCTCTGAGAATCAA                    1730    AATTCTTTCTTTGATGGCTTCCCAACAGGA          1750                1770    TACAAGGATATTGATGATAAAGGAGTTATC                    1790    TTAGCTAAAGGTAATTTCGTGATTATAGCA          1810                1830    GCTAGACCATCTATAGGGAAAACAGCTTTA                    1850    GCTATAGACATGGCGATAAATCTTGCGGTT          1870                1890    ACTCAACAGCGTAGAGTTGGTTTCCTATCA                    1910    CTAGAAATGAGCGCAGGTCAAATTGTTGAG          1930                1950    CGGATTATTGCTAATTTAACAGGAATATCT                    1970    GGTGAAAAATTACAAAGAGGGGATCTCTCT          1990                2010    AAAGAAGAATTATTCCGAGTAGAAGAAGCT                    2030    GGAGAAACGGTTAGAGAATCACATTTTTAT          2050                2070    ATCTGCAGTGATAGTCAGTATAAGCTTAAC                    2090    TTAATCGCGAATCAGATCCGGTTGCTGAGA          2110                2130    AAAGAAGATCGAGTAGACGTAATATTTATC                    2150    GATTACTTGCAGTTGATCAACTCATCGGTT          2170                2190    GGAGAAAATCGTCAAAATGAAATAGCAGAT                    2210    ATATCTAGAACCTTAAGAGGTTTAGCCTCA          2230                2250    GAGCTAAACATTCCTATAGTTTGTTTATCC                    2270    CAACTATCTAGAAAAGTTGAGGATAGAGCA          2290                2310    AATAAAGTTCCCATGCTTTCAGATTTGCGA                    2330    GACAGCGGTCAAATAGAGCAAGACGCAGAT          2350                2370    GTGATTTTGTTTATCAATAGGAAGGAATCG                    2390    TCTTCTAATTGTGAGATAACTGTTGGGAAA          2410                2430    AATAGACATGGATCGGTTTTCTCTTCGGTA                    2450    TTACATTTCGATCCAAAAATTAGTAAATTC          2470                2490    TCCGCTATTAAAAAAGTATGGTAAATTATA                    2510    GTAACTGCCACTTCATCAAAAGTCCTATCC                   ORF2>>          2530                2550    ACCTTGAAAATCAGAAGTTTGGAAGAAGAC                    2570    CTGGTCAATCTATTAAGATATCTCCCAAAT          2590                2610    TGGCTCAAAATGGGATGGTAGAAGTTATAG                    2630    GTCTTGATTTTCTTTCATCTCATTACCATG          2650                2670    CATTAGCAGCTATCCAAAGATTACTGACCG                    2690    CAACGAATTACAAGGGGAACACAAAAGGGG          2710                2730    TTGTTTTATCCAGAGAATCAAATAGTTTTC                    2750    AATTTGAAGGATGGATACCAAGAATCCGTT          2770                2790    TAACAAAAACTGAATTCTTAGAGGCTTATG                    2810    GAGTTAAGCGGTATAAAACATCCAGAAATA          2830                2850    AGTATGAGTTTAGTGGAAAAGAAGCTGAAA                    2870    CTGCTTTAGAAGCCTTATACCATTTAGGAC          2890                2910    ATCAACCGTTTTTAATAGTGGCAACTAGAA                    2930    CTCGATGGACTAATGGAACACAAATAGTAG          2950                2970    ACCGTTACCAAACTCTTTCTCCGATCATTA                    2990    GGATTTACGAAGGATGGGAAGGTTTAACTG          3010                3030    ACGAAGAAAATATAGATATAGACTTAACAC                    3050    CTTTTAATTCACCACCTACACGGAAACATA          3070                3090    AAGGGTTCGTTGTAGAGCCATGTCCTATCT                    3110    TGGTAGATCAAATAGAATCCTACTTTGTAA          3130                3150    TCAAGCCTGCAAATGTATACCAAGAAATAA                    3170    AAATGCGTTTCCCAAATGCATCAAAGTATG          3190                3210    CTTACACATTTATCGACTGGGTGATTACAG                    3230    CAGCTGCGAAAAAGAGACGAAAATTAACTA          3250                3270    AGGATAATTCTTGGCCAGAAAACTTGTTAT                    3290    TAAACGTTAACGTTAAAAGTCTTGCATATA          3310                3330    TTTTAAGGATGAATCGGTACATCTGTACAA                    3350    GGAACTGGAAAAAAATCGAGTTAGCTATCG          3370                3390    ATAAATGTATAGAAATCGCCATTCAGCTTG                    3410    GCTGGTTATCTAGAAGAAAACGCATTGAAT          3430                3450    TTCTGGATTCTTCTAAACTCTCTAAAAAAG                    3470    AAATTCTATATCTAAATAAAGAGCGCTTTG          3490                3510    AAGAAATAACTAAGAAATCTAAAGAACAAA                    3530    TGGAACAATTAGAACAAGAATCTATTAATT          3550                3570    AATAGCAAGCTTGAAACTAAAAACCTAATT                    3590    TATTTAAAGCTCAAAATAAAAAAGAGTTTT          3610                3630    AAAATGGGAAATTCTGGTTTTTATTTGTAT                    3650    AACACTGAAAACTGCGTCTTTGCTGATAATORF3 >>          3670                3690    ATCAAAGTTGGGCAAATGACAGAGCCGCTC                    3710    AAGGACCAGCAAATAATCCTTGGGACAACA          3730                3750    TCAACACCTGTCGCAGCCAAAATGACAGCT                    3770    TCTGATGGAATATCTTTAACAGTCTCCAAT          3790                3810    AATTCATCAACCAATGCTTCTATTACAATT                    3830    GGTTTGGATGCGGAAAAAGCTTACCAGCTT          3850                3870    ATTCTAGAAAAGTTGGGAGATCAAATTCTT                    3890    GATGGAATTGCTGATACTATTGTTGATAGT          3910                3930    ACAGTCCAAGATATTTTAGACAAAATCAAA                    3950    ACAGACCCTTCTCTAGGTTTGTTGAAAGCT          3970                3990    TTTAACAACTTTCCAATCACTAATAAAATT                    4010    CAATGCAACGGGTTATTCACTCCCAGTAAC          4030                4050    ATTGAAACTTTATTAGGAGGAACTGAAATA                    4070    GGAAAATTCACAGTCACACCCAAAAGCTCT          4090                4110    GGGAGCATGTTCTTAGTCTCAGCAGATATT                    4130    ATTGCATCAAGAATGGAAGGCGGCGTTGTT          4150                4170    CTAGCTTTGGTACGAGAAGGTGATTCTAAG                    4190    CCCTGCGCGATTAGTTATGGATACTCATCA          4210                4230    GGCATTCCTAATTTATGTAGTCTAAGAACC                    4250    AGTATTACTAATACAGGATTGACTCCGACA          4270                4290    ACGTATTCATTACGTGTAGGCGGTTTAGAA                    4310    AGCGGTGTGGTATGGGTTAATGCCCTTTCT          4330                4350    AATGGCAATGATATTTTAGGAATAACAAAT                    4370    ACTTCTAATGTATCTTTTTTAGAGGTAATA          4390                4410    CCTCAAACAAACGCTTAAACAATTTTTATT                    4430    GGATTTTTCTTATAGGTTTTATATTTAGAG          4450                4470    AAAACAGTTCGAATTACGGGGTTTGTTATG                    4490    CAAAATAAAAGAAAAGTGAGGGACGATTTT                       ORF4 >>          4510                4530    ATTAAAATTGTTAAAGATGTGAAAAAAGAT                    4550    TTCCCCGAATTAGACCTAAAAATACGAGTA          4570                4590    AACAAGGAAAAAGTAACTTTCTTAAATTCT                    4610    CCCTTAGAACTCTACCATAAAAGTGTCTCA          4630                4650    CTAATTCTAGGACTGCTTCAACAAATAGAA                    4670    AACTCTTTAGGATTATTCCCAGACTCTCCT          4690                4710    GTTCTTGAAAAATTAGAGGATAACAGTTTA                    4730    AAGCTAAAAAAGGCTTTGATTATGCTTATC          4750                4770    TTGTCTAGAAAAGACATGTTTTCCAAGGCT                    4790    GAATAGACAACTTACTCTAACGTTGGAGTT          4810                4830    GATTTGCACACCTTAGTTTTTTGCTCTTTT                    4850    AAGGGAGGAACTGGAAAAACAACACTTTCTORF5 >>          4870                4890    CTAAACGTGGGATGCAACTTGGCCCAATTT                    4910    TTAGGGAAAAAAGTGTTACTTGCTGACCTA          4930                4950    GACCCGCAATCCAATTTATCTTCTGGATTG                    4970    GGGGCTAGTGTCAGAAGTGACCAAAAAGGC          4990                5010    TTGCACGACATAGTATACACATCAAACGAT                    5030    TTAAAATCAATCATTTGCGAAACAAAAAAA          5050                5070    GATAGTGTGGACCTAATTCCTGCATCATTT                    5090    TCATCCGAACAGTTTAGAGAATTGGATATT          5110                5130    CATAGAGGACCTAGTAACAACTTAAAGTTA                    5150    TTTCTGAATGAGTACTGCGCTCCTTTTTAT          5170                5190    GACATCTGCATAATAGACACTCCACCTAGC                    5210    CTAGGAGGGTTAACGAAAGAAGCTTTTGTT          5230                5250    GCAGGAGACAAATTAATTGCTTGTTTAACT                    5270    CCAGAACCTTTTTCTATTCTAGGGTTACAA          5290                5310    AAGATACGTGAATTCTTAAGTTCGGTCGGA                    5330    AAACCTGAAGAAGAACACATTCTTGGAATA          5350                5370    GCTTTGTCTTTTTGGGATGATCGTAACTCG                    5390    ACTAACCAAATGTATATAGACATTATCGAG          5410                5430    TCTATTTACAAAAACAAGCTTTTTTCAACA                    5450    AAAATTCGTCGAGATATTTCTCTCAGCCGT          5470                5490    TCTCTTCTTAAAGAAGATTCTGTAGCTAAT                    5510    GTCTATCCAAATTCTAGGGCCGCAGAACAT          5530                5550    ATTCTGAAGTTAACGCATGAAATAGCAAAT                    5570    ATTTTGCATATCGAATATGAACGAGATTAC          5590                5610    TCTCAGAGGACAACGTGAACAAACTAAAAA                    5630    AAGAAGCGGATGTCTTTTTTAAAAAAAATC          ORF6 >>          5650                5670    AAACTGCCGCTTCTCTAGATTTTAAGAAGA                    5690    CGCTTCCCTCCATTGAACTATTCTCAGCAA          5710                5730    CTTTGAATTCTGAGGAAAGTCAGAGTTTGG                    5750    ATCGATTATTTTTATCAGAGTCCCAAAACT          5770                5790    ATTCGGATGAAGAATTTTATCAAGAAGACA                    5810    TCCTAGCGGTAAAACTGCTTACTGGTCAGA          5830                5850    TAAAATCCATACAGAAGCAACACGTACTTC                    5870    TTTTAGGAGAAAAAATCTATAATGCTAGAA          5890                5910    AAATCCTGAGTAAGGATCACTTCTCCTCAA                    5930    CAACTTTTTCATCTTGGATAGAGTTAGTTT          5950                5970    TTAGAACTAAGTCTTCTGCTTACAATGCTC                    5990    TTGCATATTACGAGCTTTTTATAAACCTCC          6010                6030    CCAACCAAACTCTACAAAAAGAGTTTCAAT                    6050    CGATCCCCTATAAATCCGCATATATTTTGG          6070                6090    CCGCTAGAAAAGGCGATTTAAAAACCAAGG                    6110    TCGATGTGATAGGGAAAGTATGTGGAATGT          6130                6150    CGAACTCATCGGCGATAAGGGTGTTGGATC                    6170    AATTTCTTCCTTCATCTAGAAACAAAGACG          6190                6210    TTAGAGAAACGATAGATAAGTCTGATTCAG                    6230    AGAAGAATCGCCAATTATCTGATTTCTTAA          6250                6270    TAGAGATACTTCGCATCATGTGTTCCGGAG                    6290    TTTCTTTGTCCTCCTATAACGAAAATCTTC          6310                6330    TACAACAGCTTTTTGAACTTTTTAAGCAAA                    6350    AGAGCTGATCCTCCGTCAGCTCATATATAT          6370                6390    ATATCTATTATATATATATATTTAGGGATT                    6410    TGATTTCACGAGAGAGATTTGCAACTCTTG          6430                6450    GTGGTAGACTTTGCAACTCTTGGTGGTAGA                    6470    CTTTGCAACTCTTGGTGGTAGACTTTGCAA          6490                6510    CTCTTGGTGGTAGACTTGGTCATAATGGAC                    6530    TTTTGTTAAAAAATTTATTAAAATCTTAGA          6550                6570    GCTCCGATTTTGAATAGCTTTGGTTAAGAA                    6590    AATGGGCTCGATGGCTTTCCATAAAAGTAG               ORF7 >>          6610                6630    ATTGTTTTTAACTTTTGGGGACGCGTCGGA                    6650    AATTTGGTTATCTACTTTATCTTATCTAAC          6670                6690    TAGAAAAAATTATGCGTCTGGGATTAACTT                    6710    TCTTGTTTCTTTAGAGATTCTGGATTTATC          6730                6750    GGAAACCTTGATAAAGGCTATTTCTCTTGA                    6770    CCACAGCGAATCTTTGTTTAAAATCAAGTC          6790                6810    TCTAGATGTTTTTAATGGAAAAGTTGTTTC                    6830    AGAGGCATCTAAACAGGCTAGAGCGGCATG          6850                6870    CTACATATCTTTCACAAAGTTTTTGTATAG                    6890    ATTGACCAAGGGATATATTAAACCCGCTAT          6910                6930    TCCATTGAAAGATTTTGGAAACACTACATT                    6950    TTTTAAAATCCGAGACAAAATCAAAACAGA          6970                6990    ATCGATTTCTAAGCAGGAATGGACAGTTTT                    7010    TTTTGAAGCGCTCCGGATAGTGAATTATAG          7030                7050    AGACTATTTAATCGGTAAATTGATTGTACA                    7070    AGGGATCCGTAAGTTAGACGAAATTTTGTC          7090                7110    TTTGCGCACAGACGATCTATTTTTTGCATC                    7130    CAATCAGATTTCCTTTCGCATTAAAAAAAG          7150                7170    ACAGAATAAAGAAACCAAAATTCTAATCAC                    7190    ATTTCCTATCAGCTTAATGGAAGAGTTGCA          7210                7230    AAAATACACTTGTGGGAGAAATGGGAGAGT                    7250    ATTTGTTTCTAAAATAGGGATTCCTGTAAC          7270                7290    AACAAGTCAGGTTGCGCATAATTTTAGGCT                    7310    TGCAGAGTTCCATAGTGCTATGAAAATAAA          7330                7350    AATTACTCCCAGAGTACTTCGTGCAAGCGC                    7370    TTTGATTCATTTAAAGCAAATAGGATTAAA          7390                7410    AGATGAGGAAATCATGCGTATTTCCTGTCT                    7430    TTCATCGAGACAAAGTGTGTGTTCTTATTG          7450                7470    TTCTGGGGAAGAGGTAATTCCTCTAGTACA                    7490    AACACCCACAATATTGTGATATAATTAAAATT.

2. An isolated ORF3 gene comprising the nucleotide sequence 3604 through 4398, SEQ ID NO:11, according to claim 1.

3. An isolated ORF4 gene comprising the nucleotide sequence 4468 through 4773, SEQ ID NO:3, according to claim 1.

4. A recombinant expression vector comprising the ORF3 of claim 2.

5. A recombinant expression vector comprising the ORF4 of claim 3.

6. Escherichia coli transformed by the expression vector of claim 4.

7. Escherichia coli transformed by the expression vector of claim 5.

8. A recombinant expression vector comprising at least one gene selected from the group consisting of ORF3 comprising the nucleotide sequence 3604 through 4398, SEQ ID NO:11 and ORF4 comprising the nucleotide sequence 4468 through 4776, SEQ ID NO:13, as set forth in claim 1.

9. Escherichia coli transformed by the expression vector of claim 8.